<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPT</journal-id>
<journal-id journal-id-type="hwp">spcpt</journal-id>
<journal-id journal-id-type="nlm-ta">J Cardiovasc Pharmacol Ther</journal-id>
<journal-title>Journal of Cardiovascular Pharmacology and Therapeutics</journal-title>
<issn pub-type="ppub">1074-2484</issn>
<issn pub-type="epub">1940-4034</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1074248413491496</article-id>
<article-id pub-id-type="publisher-id">10.1177_1074248413491496</article-id> 
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Traditional Heart Failure Medications and Sudden Cardiac Death Prevention</article-title>
<subtitle>A Review</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Al Chekakie</surname>
<given-names>M. Obadah</given-names>
</name>
<degrees>MD, MSc, FACC</degrees>
<xref ref-type="aff" rid="aff1-1074248413491496">1</xref>
<xref ref-type="corresp" rid="corresp1-1074248413491496"/>
</contrib>
</contrib-group>
<aff id="aff1-1074248413491496">
<label>1</label>Cheyenne Regional Medical Center, University of Colorado, Cheyenne, Wyoming, WY, USA</aff>
<author-notes>
<corresp id="corresp1-1074248413491496">M. Obadah Al Chekakie, Cheyenne Regional Medical Center, University of Colorado, 214 East 23rd Street, Cheyenne, WY 82001, USA. Email: <email>obadac@gmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2013</year>
</pub-date>
<volume>18</volume>
<issue>5</issue>
<fpage>412</fpage>
<lpage>426</lpage>
<history>
<date date-type="received">
<day>15</day>
<month>12</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>2</day>
<month>5</month>
<year>2013</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Sudden cardiac death (SCD) is still a major public health issue with an estimated annual incidence ranging from 184,000 to &gt; 400,000 per year. The ACC/AHA/ESC 2006 guidelines define SCD as “death from an unexpected circulatory arrest, usually due to a cardiac arrhythmia occurring within an hour of the onset of symptoms”. A recent study of sudden cardiac death using multiple sources of ascertainment found that coronary artery disease was present in more than 50% of patients older than 35 years who died suddenly and underwent autopsy. Antiarrhythmic drugs have failed to show any mortality benefit even when compared to placebo or implantable cardiovertor defibrillators (ICDs). While patients with systolic heart failure are at higher risk of dying suddenly, most of the patients experiencing sudden cardiac death have left ventricular ejection fraction (LVEF) &gt; 50%. β-blockers, Angiotensin enzymes (ACE) inhibitors as well as aldosterone antagonists prevent ischemia and remodelling in the left ventricle especially in post myocardial infarction (MI) patients and in patients with systolic heart failure. This article will review the data on the effects of traditional heart failure medications, especially β-blockers, Renin Angiotensin system blockers, as well as Statin therapy on sudden cardiac death in post MI patients and in patients with systolic heart failure.</p>
</abstract>
<kwd-group>
<kwd>sudden cardiac death</kwd>
<kwd>renin–angiotensin–aldosterone system</kwd>
<kwd>statin</kwd>
<kwd>heart failure</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1074248413491496">
<title>Introduction</title>
<p>Sudden cardiac death (SCD) is still a major public health issue with an estimated annual incidence ranging from 184 000 to &gt; 400 000 per year.<sup>
<xref ref-type="bibr" rid="bibr1-1074248413491496">1</xref>
<xref ref-type="bibr" rid="bibr2-1074248413491496"/>
<xref ref-type="bibr" rid="bibr3-1074248413491496"/>–<xref ref-type="bibr" rid="bibr4-1074248413491496">4</xref>
</sup> The American College of Cardiology/ American Heart Association/ European Society of Cardiology 2006 guidelines define SCD as “death from an unexpected circulatory arrest, usually due to a cardiac arrhythmia occurring within an hour of the onset of symptoms.”<sup>
<xref ref-type="bibr" rid="bibr5-1074248413491496">5</xref>
</sup> The World Health Organization defines SCD as “sudden, unexpected death either within 1 hour of symptom onset (event witnessed) or within 24 hours of having been observed alive and symptom free (un-witnessed).”<sup>
<xref ref-type="bibr" rid="bibr6-1074248413491496">6</xref>
</sup> The SCD estimation is difficult, and there is a wide range reported in the studies.<sup>
<xref ref-type="bibr" rid="bibr1-1074248413491496">1</xref>
<xref ref-type="bibr" rid="bibr2-1074248413491496"/>
<xref ref-type="bibr" rid="bibr3-1074248413491496"/>–<xref ref-type="bibr" rid="bibr4-1074248413491496">4</xref>
</sup> This is due to reliance on death certificates in earlier studies, which can over- or underestimate the incidence of SCD.<sup>
<xref ref-type="bibr" rid="bibr7-1074248413491496">7</xref>
</sup> Furthermore, there is poor agreement between autopsy diagnosis and death certificates.<sup>
<xref ref-type="bibr" rid="bibr8-1074248413491496">8</xref>
<xref ref-type="bibr" rid="bibr9-1074248413491496"/>–<xref ref-type="bibr" rid="bibr10-1074248413491496">10</xref>
</sup> Using prospective and multiple sources of ascertainment including review of medical records, analysis of circumstances of death and autopsy data when available are important methods that can help better estimate the true incidence of SCD.<sup>
<xref ref-type="bibr" rid="bibr3-1074248413491496">3</xref>,<xref ref-type="bibr" rid="bibr11-1074248413491496">11</xref>
</sup> But of the 6 original source studies reporting primary data on SCD, only 2 studies were prospective.<sup>
<xref ref-type="bibr" rid="bibr3-1074248413491496">3</xref>,<xref ref-type="bibr" rid="bibr6-1074248413491496">6</xref>,<xref ref-type="bibr" rid="bibr11-1074248413491496">11</xref>
</sup> A recent study of SCD using multiple sources of ascertainment found that coronary artery disease was present in more than 50% of the patients older than 35 years who had SCD and underwent autopsy.<sup>
<xref ref-type="bibr" rid="bibr3-1074248413491496">3</xref>
</sup> It is also important to note that patients presenting with ventricular fibrillation/ventricular tachycardia (VF/VT) are more likely to survive than patients presenting with asystole or pulseless electrical activity (25% vs 2%, respectively).<sup>
<xref ref-type="bibr" rid="bibr3-1074248413491496">3</xref>
</sup> Antiarrhythmic drugs have failed to show any mortality benefit even when compared to placebo or implantable cardioverter defibrillators (ICDs).<sup>
<xref ref-type="bibr" rid="bibr12-1074248413491496">12</xref>
</sup> Although patients with systolic heart failure are at higher risk of dying suddenly, most of the patients experiencing SCD have left ventricular ejection fraction (LVEF) &gt;50%. Measuring LVEF has its own pitfalls and alone is not sufficient as a risk predictor.<sup>
<xref ref-type="bibr" rid="bibr13-1074248413491496">13</xref>,<xref ref-type="bibr" rid="bibr14-1074248413491496">14</xref>
</sup> Relying on the left ventricular (LV) function alone is not enough when making health care policy, especially since majority of sudden cardiac arrests are the first arrhythmic event a patient experiences and could be the first presentation of coronary artery disease.<sup>
<xref ref-type="bibr" rid="bibr15-1074248413491496">15</xref>
</sup> Measuring LV mass and the presence of LV hypertrophy can predict SCD and add to risk stratification even in patients with low LVEF.<sup>
<xref ref-type="bibr" rid="bibr16-1074248413491496">16</xref>,<xref ref-type="bibr" rid="bibr17-1074248413491496">17</xref>
</sup> Furthermore, patients with New York Heart Association (NYHA) functional class III and IV systolic heart failure are at high risk of sudden death,<sup>
<xref ref-type="bibr" rid="bibr18-1074248413491496">18</xref>,<xref ref-type="bibr" rid="bibr19-1074248413491496">19</xref>
</sup> and exercise tolerance is an important predictor of survival in patients with advanced systolic heart failure independent of LVEF.<sup>
<xref ref-type="bibr" rid="bibr20-1074248413491496">20</xref>
</sup> β-Blockers, angiotensin enzyme (ACE) inhibitors, and aldosterone antagonists prevent ischemia and remodeling in the left ventricle, especially in post-myocardial infarction (MI) patients and in patients with systolic heart failure. This article will review the data on the effects of traditional heart failure medications, especially β-blockers and renin–angiotensin system blockers as well as statin therapy on SCD in post-MI patients and in patients with systolic heart failure.</p>
<sec id="section2-1074248413491496">
<title>β-Blockers and SCD Prevention</title>
<sec id="section3-1074248413491496">
<title>Potential Mechanisms of β-Blockers on SCD Prevention</title>
<p>Multiple studies have suggested that the major mechanisms responsible for the cardiac arrhythmias associated with SCD are VT and VF. For these arrhythmias to occur, an interaction between substrate (ventricular enlargement and/or hypertrophy and myocardial scar due to ischemic or nonischemic injury) and triggers (electrolyte abnormalities, changes in the sympathetic and parasympathetic activity, neurohumoral factors, and premature ventricular contractions) is necessary to initiate reentry leading to VT and VF (<xref ref-type="fig" rid="fig1-1074248413491496">Figure 1</xref>). Even in the setting of early MI (&lt;48 hours), VT can occur and is mostly due to reentry caused by the electrical inhomogeneity of the ischemic myocardium.<sup>
<xref ref-type="bibr" rid="bibr21-1074248413491496">21</xref>
</sup> Other mechanisms such as triggered activity and increased automaticity could also be involved. Early VF after MI (&lt;48 hours) can occur without LV dysfunction. Late VF (&gt;48 hours) occurs mainly in the setting of large infarcts, typically in the anterior wall and is mostly thought to be due to reentry.<sup>
<xref ref-type="bibr" rid="bibr21-1074248413491496">21</xref>
</sup> In any reentry circuit, there is an excitable gap. An excitable gap is the region between the head and the tail of the preceding reentrant wave front that is capable of being excited (no longer refractory). The larger the excitable gap, the more likely a stimulus is capable of initiating or terminating the tachycardia. Arrhythmias with smaller excitable gaps are less likely to sustain.<sup>
<xref ref-type="bibr" rid="bibr22-1074248413491496">22</xref>
</sup>
</p>
<fig id="fig1-1074248413491496" position="float">
<label>Figure 1.</label>
<caption>
<p>Diagram showing the interaction of various substrate and triggers that modulate potential arrhythmogenic mechanisms that lead to ventricular tachycardia and fibrillation, which are the most common arrhythmias causing sudden cardiac death. SCD indicates sudden cardiac death.</p>
</caption>
<graphic xlink:href="10.1177_1074248413491496-fig1.tif"/>
</fig>
<p>Many anatomic or functional substrates such as coronary artery disease, cardiomyopathy, or primary electrophysiological disease can lead to SCD. Progression of these disease states leads to sympathetic activation. At the cellular level, sympathetic and vagal denervation caused by myocardial ischemia leads to an increase in interstitial potassium and intracellular calcium concentrations.<sup>
<xref ref-type="bibr" rid="bibr15-1074248413491496">15</xref>
</sup> Sympathetic activation results in protein kinase A phosphorylation of the ryanodine receptors (RyR2) leading to diastolic release of calcium from sarcoplasmic reticulum, which increases after depolarizations that can be the trigger for ventricular arrhythmias.<sup>
<xref ref-type="bibr" rid="bibr23-1074248413491496">23</xref>
</sup> β<sub>1</sub> receptor stimulation can also lead to phosphorylation of the RyR2 receptor via a pathway independent of protein kinase A by activating an exchange protein directly activated by cyclic adenosine monophosphate (cAMP; Epac). This leads to phosphorylation of the RyR2 receptors and calcium leak from the sarcoplasmic reticulum.<sup>
<xref ref-type="bibr" rid="bibr24-1074248413491496">24</xref>
</sup> Blocking β<sub>1</sub> receptors prevents this calcium leak. Furthermore, increased intracellular calcium leads to partial membrane depolarization that causes a decrease in the steady state availability of fast sodium channels.<sup>
<xref ref-type="bibr" rid="bibr25-1074248413491496">25</xref>
</sup> The area of damaged or diseased myocardium does not need to be large to create reentry. Often, ischemic myocardium is adjacent to healthy myocardial tissue, which leads to heterogeneity of conduction and creates the substrate that leads to ventricular arrhythmias when a timely trigger (from early or delayed after depolarizations) occurs.<sup>
<xref ref-type="bibr" rid="bibr26-1074248413491496">26</xref>
</sup>
</p>
<p>As myocardial ischemia progresses, the neurohumoral system exerts further stimulation of the sympathetic system and the renin–angiotensin–aldosterone system (RAAS). This neurohumoral cascade leads to increasing levels of norepinephrine, angiotensin II, aldosterone, endothelin, and vasopressin. Increased norepinephrine levels lead to increased preload and afterload, which in turn increases myocardial oxygen demand. Furthermore, the activation of these systems promotes fibrosis and necrosis,<sup>
<xref ref-type="bibr" rid="bibr27-1074248413491496">27</xref>
<xref ref-type="bibr" rid="bibr28-1074248413491496"/>–<xref ref-type="bibr" rid="bibr29-1074248413491496">29</xref>
</sup> which over time will lead to cardiac remodeling, LV dilatation, fibrosis, and progression into heart failure.<sup>
<xref ref-type="bibr" rid="bibr30-1074248413491496">30</xref>
</sup>
</p>
<p>Three types of β receptors are known, designated β<sub>1</sub>, β<sub>2</sub>, and β<sub>3</sub> receptors. β<sub>1</sub> receptors are located mainly in the heart and in the kidneys and are downregulated in heart failure due to chronically elevated norepinephrine levels. β<sub>2</sub> receptors are located mainly in the lungs, gastrointestinal tract, liver, uterus, vascular smooth muscle, and skeletal muscle. β<sub>3</sub> receptors are located in fat cells, and they have activity in the heart. β<sub>3</sub> receptor expression in the heart is increased after 4 weeks of exercise, and they are important in regulating endothelial nitric oxide synthase and are necessary for regulating and mediating the cardioprotective effects of exercise.<sup>
<xref ref-type="bibr" rid="bibr31-1074248413491496">31</xref>
</sup> β<sub>1</sub> and β<sub>2</sub> receptors activate cAMP that acts as a second messenger and leads to increased contractility (inotropy), increased heart rate (which increases myocardial oxygen demand), increased conduction velocity (which may promote reentry), and have a positive lusitropic effect that improves active relaxation.<sup>
<xref ref-type="bibr" rid="bibr32-1074248413491496">32</xref>
</sup> β<sub>2</sub> receptors promote the release of renin, which in turn activates angiotensin II and aldosterone, both of which elevate the blood pressure, increase afterload, promote potassium wasting, and activate fibroblasts leading to fibrosis. β-Blockers are considered as class II antiarrhythmic medications. They decrease spontaneous depolarization, prolong the sinus node cycle length, atrioventricular conduction times, and atrioventricular refractory periods. β-Blockers exert their protective effect on the heart via different mechanisms. β-Blockers reduce ischemia by decreasing the heart rate, which is the major determinant of myocardial oxygen demand.<sup>
<xref ref-type="bibr" rid="bibr33-1074248413491496">33</xref>
</sup> At the cellular level, β-blockers decrease electrical excitability by limiting calcium entry via catecholamine-dependent channels.<sup>
<xref ref-type="bibr" rid="bibr24-1074248413491496">24</xref>,<xref ref-type="bibr" rid="bibr34-1074248413491496">34</xref>
</sup> They also restore cardiac ryanodine receptor channel function in patients with heart failure, and they upregulate β receptor density.<sup>
<xref ref-type="bibr" rid="bibr23-1074248413491496">23</xref>
</sup> All this helps decrease LV mass and volume, decrease LV end-diastolic pressure, and improve LV and RV function.<sup>
<xref ref-type="bibr" rid="bibr23-1074248413491496">23</xref>,<xref ref-type="bibr" rid="bibr35-1074248413491496">35</xref>
</sup> β-Blockers improve LV function over time in patients with systolic heart failure, and this is evident after 1 to 3 months of therapy and continues over time. By 18 months, the LV geometry also improves, and the heart becomes less spherical.<sup>
<xref ref-type="bibr" rid="bibr36-1074248413491496">36</xref>
</sup> However, this does not occur in all patients with systolic heart failure. Several studies suggest that the presence of hibernating myocardium predicts response to β-blocker therapy, and segments that show extensive scarring (&gt;75% of gadolinium enhancement) are less likely to improve.<sup>
<xref ref-type="bibr" rid="bibr37-1074248413491496">37</xref>,<xref ref-type="bibr" rid="bibr38-1074248413491496">38</xref>
</sup> In a subanalysis of The Multicenter Automatic Defibrillator Implantation Trial II (MADIT–II) trial, the benefit of implanting an ICD was found to be time dependent, with benefit extending for patients who had a long history of poor LV systolic function and remote MI despite receiving β-blockers.<sup>
<xref ref-type="bibr" rid="bibr39-1074248413491496">39</xref>
</sup> Furthermore, β-blockers have been shown to decrease the frequency of ICD shocks,<sup>
<xref ref-type="bibr" rid="bibr40-1074248413491496">40</xref>
</sup> and they increase the success of antitachycardia pacing.<sup>
<xref ref-type="bibr" rid="bibr41-1074248413491496">41</xref>
</sup> All these data suggest the benefit of β-blockers on survival is not explained only by the improvement in LV function.</p>
</sec>
<sec id="section4-1074248413491496">
<title>Effect of β-Blockers on SCD Prevention in Post-MI Patients</title>
<p>β-Blockers were studied in the post-MI patients since the 1960s when propranolol was found to reduce the mortality after acute MI.<sup>
<xref ref-type="bibr" rid="bibr42-1074248413491496">42</xref>
</sup> Pivotal trials such as the <italic>Norwegian Multicenter Study Group</italic> (utilizing Timolol at a starting dose of 5 mg/d with target of 20 mg/d), <italic>β-blocker Heart Attack Trial</italic> (<italic>BHAT</italic>, utilizing propranolol at a dose of 180-240 mg/d) in the 1980s showed reduction in total mortality and SCD.<sup>
<xref ref-type="bibr" rid="bibr43-1074248413491496">43</xref>,<xref ref-type="bibr" rid="bibr44-1074248413491496">44</xref>
</sup> The benefit of β-blockers post-MI was seen even in patients taking ACE inhibitors. The <italic>Survival and Ventricular Enlargement (SAVE)</italic> and <italic>Acute Infarction Ramipril Efficacy (AIRE)</italic> trials demonstrated that β-blockers provided additional reduction in cardiovascular mortality independent of the use of ACE inhibitors.<sup>
<xref ref-type="bibr" rid="bibr45-1074248413491496">45</xref>,<xref ref-type="bibr" rid="bibr46-1074248413491496">46</xref>
</sup>
</p>
<p>A meta-analysis evaluated several randomized clinical trials looking at the benefits of β-blockers treatment post-MI. This analysis revealed a significant reduction in mortality with β-blocker therapy (hazard ratio [HR] = 0.77, 95% confidence interval [CI] 0.69-0.85).<sup>
<xref ref-type="bibr" rid="bibr47-1074248413491496">47</xref>
</sup> Despite this, β-blockers are underutilized as was shown by the Cooperative Cardiovascular Project, an observational study that evaluated the care of 200 000 Medicare patients with the diagnosis of MI. Only 34% of the patients were given β-blockers. The mortality reduction in patients who were prescribed β-blockers at the time of discharge from the hospital was 40%.<sup>
<xref ref-type="bibr" rid="bibr48-1074248413491496">48</xref>
</sup>
</p>
<p>Even patients who have depressed LV systolic function post-MI benefit from β-blockers as shown by a subanalysis of <italic>BHAT</italic> trial.<sup>
<xref ref-type="bibr" rid="bibr49-1074248413491496">49</xref>
</sup> The <italic>Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction trial (CAPRICORN)</italic> trial specifically addressed this patient population. The <italic>CAPRICORN</italic> was a prospective, randomized trial recruiting patients with recent acute MI (3-21 days) and LV dysfunction with ejection fraction (EF) ≤40%. A total of 984 patients were placed on placebo and 975 patients were allocated to carvedilol therapy post-MI with an average follow-up of 1.3 years. The initial starting dose was 6.25 mg orally twice daily with target dose of 25 mg orally twice daily. All-cause mortality was lower in the carvedilol group than in the placebo group (HR 0.77, 95% CI 0.60-0.98, <italic>P</italic> = .03).<sup>
<xref ref-type="bibr" rid="bibr50-1074248413491496">50</xref>
</sup> Patients taking carvedilol had a significant reduction in malignant ventricular arrhythmias (HR 0.37, 95% CI 0.24-0.58; <italic>P</italic> &lt; .0001).<sup>
<xref ref-type="bibr" rid="bibr51-1074248413491496">51</xref>
</sup> It is important to emphasize that in this trial 98% of the patients were treated with an ACE inhibitor.</p>
</sec>
<sec id="section5-1074248413491496">
<title>Effect of β-Blockers on SCD Prevention in Patients With Systolic Heart Failure</title>
<p>β-Blockers were initially thought to be contraindicated in patients with heart failure due to their negative inotropic effects in the short term. However, later studies showed they consistently improve morbidity and mortality in patients with heart failure; they also lead to a 40% reduction in hospitalization. The first is the <italic>US Carvedilol trial</italic> that enrolled 1094 patients with congestive heart failure (CHF) and LVEF of ≤35%. Patients were assigned to 4 treatment protocols based on exercise capacity. Within each protocol, patients were assigned to either placebo (n = 398) or carvedilol (n = 696). Although this trial was not designed as a mortality trial, it demonstrated a 65% decrease in the risk of death with carvedilol compared to placebo (<italic>P</italic> &lt; .001). Sudden death was reduced from 3.8% in the placebo group to 1.7% in the carvedilol group.<sup>
<xref ref-type="bibr" rid="bibr52-1074248413491496">52</xref>
</sup>
</p>
<p>
<italic>The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial</italic> examined the effect of carvedilol in 2289 patients with severe CHF, defined as dyspnea at rest and LVEF ≤25%. This trial validated the mortality benefit of carvedilol in patients with severe heart failure with a 50% reduction in all-cause mortality (HR 0.50, 95% CI of 0.10-0.63, <italic>P</italic> &lt; .01).<sup>
<xref ref-type="bibr" rid="bibr53-1074248413491496">53</xref>
</sup> Unfortunately, this trial did not have data available on the impact of carvedilol on sudden death.</p>
<p>
<italic>The Cardiac Insufficiency Bisoprolol Study (CIBIS) II</italic> was a multicenter, double-blind, randomized, placebo-controlled trial that evaluated the efficacy of bisoprolol in reducing the incidence of all-cause mortality in heart failure. Bisoprolol is a selective β<sub>1</sub> receptor blocker, and the target dose was 10 mg daily. All patients enrolled received standard therapy with diuretics and ACE inhibitors (ACE-I). A total of 2647 patients with NYHA class III or IV with LVEF of ≤35% were randomized to either bisoprolol (n = 1327) or placebo (n = 1320). This study was stopped prematurely because bisoprolol showed a significant mortality benefit. Death from any cause in the Bisoprolol group was 11.8% versus 17.3% in the placebo group (HR 0.66, 95% CI 0.54-0.80, <italic>P</italic> = .0001). Sudden death was also reduced in the bisoprolol group by 42% compared to the placebo group (HR = 0.56, 95% CI 0.39-0.80, <italic>P</italic> = .0011).<sup>
<xref ref-type="bibr" rid="bibr54-1074248413491496">54</xref>
</sup>
</p>
<p>
<italic>The Metoprolol CR/XL Randomized Intervention Trial in CHF (MERIT-HF) </italic>is a double-blind randomized controlled study that included 3991 patients with CHF and NYHA class II to IV with an LVEF of ≤40%. These patients were stable on optimal medical therapy. This trial evaluated whether controlled release/extended release formulation of metoprolol taken daily would reduce mortality in this patient population. The starting dose was 12.5 mg once daily with target dose of 200 mg orally once daily. Patients were randomized to metoprolol CR/XL (n = 1990) uptitrated to 200 mg daily over and 8-week period of time or placebo (n = 2001). The trial demonstrated a 34% relative risk reduction in all-cause mortality with controlled release/extended release formulation of metoprolol. The MERIT-HF showed a 41% relative risk reduction in sudden death.<sup>
<xref ref-type="bibr" rid="bibr55-1074248413491496">55</xref>
</sup>
</p>
<p>
<italic>The β-blocker Evaluation of Survival (BEST)</italic> Trial showed a statistically nonsignificant trend toward reduced mortality with bucindolol in 2708 patients with mild to moderate HF and LVEF of &lt;35% (HR 0.90, 95% CI 0.78-1.01, <italic>P</italic> = .10).<sup>
<xref ref-type="bibr" rid="bibr56-1074248413491496">56</xref>
</sup> There are significant differences between this trial and CIBIS II, COPERNICOUS, and MERIT-HF trials. When the BEST study population was adjusted to exclude older patients (&gt;80 years of age), patients with systolic blood pressure &lt;100 mm Hg and heart rate &lt;60 bpm (which were exclusion criteria for the other trials), bucindolol treatment was associated with significantly lower risk of death from all causes (HR = 0.77, 95% CI = 0.65-0.92) and sudden death (HR = 0.77, 95% CI 0.59-0.999).<sup>
<xref ref-type="bibr" rid="bibr57-1074248413491496">57</xref>
</sup> This suggests that the differences observed related to the population differences between these trials. However, further research needs to be done to further clarify this issue.</p>
<p>The only β-blockers approved for the treatment of heart failure in the Unites States include carvedilol, metoprolol succinate and bisoprolol. Carvedilol is a third-generation nonselective β-blocker that also blocks α<sub>1</sub> receptor and has a 12-fold higher affinity to the β<sub>1</sub> receptor compared to metoprolol. Furthermore, it does not upregulate the β receptors in the heart as does metoprolol. It also inhibits smooth muscle mitogenesis and attenuates oxygen-free radical-initiated lipid peroxidation independent of its adrenoceptor-blocking activity.<sup>
<xref ref-type="bibr" rid="bibr58-1074248413491496">58</xref>
</sup> Metoprolol Succinate crosses the blood–brain barrier and rarely can cause nightmares and severe depression.<sup>
<xref ref-type="bibr" rid="bibr59-1074248413491496">59</xref>
</sup> This led some investigators to conclude that carvedilol is superior to metoprolol Succinate in patients with heart failure. However, both agents improve LV function and survival, and both have been shown to decrease hospitalizations as discussed earlier.<sup>
<xref ref-type="bibr" rid="bibr53-1074248413491496">53</xref>,<xref ref-type="bibr" rid="bibr55-1074248413491496">55</xref>,<xref ref-type="bibr" rid="bibr60-1074248413491496">60</xref>
</sup> It is always best to continue β-blockers during hospitalization for heart failure. In the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE–HF) registry, patients who discontinued β-blockers had higher mortality compared to those who continued on β-blockers (HR 2.3, 95% CI 1.2-4.6, <italic>P</italic> = .013) and had similar risk of death as the patients who were eligible but did not receive β-blockers.<sup>
<xref ref-type="bibr" rid="bibr61-1074248413491496">61</xref>
</sup> There is no difference on the benefit obtained in patients with diabetes (risk ratio [RR] 0.77, 95% CI 0.61-0.96) versus nondiabetic patients (RR 0.65, 95% CI 0.57-0.74) or in black versus white patients. Furthermore, there is an inverse relationship between β-blockers dose and the combined all-cause mortality and all-cause hospitalization.<sup>
<xref ref-type="bibr" rid="bibr62-1074248413491496">62</xref>
</sup> Despite this, only 17.5% and 7.9% of patients were receiving target doses of metoprolol Succinate and carvedilol, respectively, within 90 days of discharge.<sup>
<xref ref-type="bibr" rid="bibr63-1074248413491496">63</xref>
</sup> This could be due to the lack of access to frequent follow-up, to the lack of understanding of the importance of uptitration to maximum dose, to slower titration protocols, or to fear of poor tolerability of higher doses. The guidelines emphasize uptitration to maximum tolerated dose within 90 days of initiating treatment.<sup>
<xref ref-type="bibr" rid="bibr64-1074248413491496">64</xref>
</sup> <xref ref-type="table" rid="table1-1074248413491496">Table 1</xref> lists the major trials examining the effects of β-blockers in patients with systolic heart failure.</p>
<table-wrap id="table1-1074248413491496" position="float">
<label>Table 1.</label>
<caption>
<p>Major Trials Examining the Effects of β-Blockers in Patients With Systolic Heart Failure.</p>
</caption>
<graphic alternate-form-of="table1-1074248413491496" xlink:href="10.1177_1074248413491496-table1.tif"/>
<table>
<thead>
<tr>
<th>Study</th>
<th>Medication</th>
<th>Mechanism</th>
<th>N</th>
<th>Entry LVEF, %</th>
<th>Target Dose</th>
<th>Effects on All-Cause Mortality</th>
<th>Effects on Sudden Cardiac Death</th>
</tr>
</thead>
<tbody>
<tr>
<td>US Carvedilol</td>
<td>Carvedilol</td>
<td>Blocks β<sub>1</sub>, β<sub>2</sub>, and α receptors</td>
<td>1094</td>
<td>&lt;35</td>
<td>6.25 to 50 mg twice daily</td>
<td>HR 0.35, 95% CI 0.20-0.61, <italic>P</italic> &lt; .001</td>
<td>1.7% with Carvedilol compared to 3.8% in placebo</td>
</tr>
<tr>
<td>CIBIS-II</td>
<td>Bisoprolol</td>
<td>β<sub>1</sub> selective blocker</td>
<td>2647</td>
<td>&lt;35</td>
<td>10 mg once daily</td>
<td>HR 0.66, 95% CI, 0.54-0.80, <italic>P </italic>= .0001</td>
<td>HR 0.56, 95% CI 0.39-0.80, <italic>P</italic> = .0011</td>
</tr>
<tr>
<td>MERIT-HF</td>
<td>Metorprolol CR/XL</td>
<td>β<sub>1</sub> selective blocker</td>
<td>3991</td>
<td>&lt;40</td>
<td>200 mg once daily</td>
<td>HR 0.66, 95% CI 0.53-0.81, <italic>P</italic> &lt; .001</td>
<td>HR 0.59, CI 0.45-0.78, <italic>P </italic>= .0002</td>
</tr>
<tr>
<td>BEST</td>
<td>Bucindolol</td>
<td>Blocks β<sub>1</sub>, β<sub>2</sub>, and α receptors</td>
<td>2708</td>
<td>&lt;35</td>
<td>50-100 mg twice daily</td>
<td>HR 0.90, 95% CI 0.78-1.0, <italic>P</italic> = .10</td>
<td>NA</td>
</tr>
<tr>
<td>COPERNICUS</td>
<td>Carvedilol</td>
<td>Blocks β<sub>1</sub>, β<sub>2</sub>, and α receptors</td>
<td>2289</td>
<td>
</td>
<td>25 mg twice daily</td>
<td>HR 0.77, 95% CI of 0.60-0.98, <italic>P</italic> = .03</td>
<td>HR 0.37, 95% CI 0.24 to 0.58, <italic>P</italic> &lt; .0001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1074248413491496">
<p>Abbreviations: N, number of patients; LVEF, left ventricular ejection fraction; HR, hazard ratio; COPERNICUS, Carvedilol Prospective Randomized Cumulative Survival;<bold> </bold>CIBIS-II, Cardiac Insufficiency Bisoprolol Study II;<bold> </bold>MERIT-HF, Metoprolol CR/XL Randomized Intervention Trial in CHF; BEST, β-blocker Evaluation of Survival; CI, confidence interval; NA, not available.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section6-1074248413491496">
<title>Effect of β-Blockers on SCD Prevention in Patients Who Survived Cardiac Arrest</title>
<p>In patients who have ICDs, β-blockers have been shown to decrease the frequency of ICD shocks.<sup>
<xref ref-type="bibr" rid="bibr40-1074248413491496">40</xref>
</sup> In an analysis of the <italic>Antiarrhythmics Versus Implantable Defibrillators Registry</italic> (<italic>AVID registry</italic>), β-blockers were associated with lower mortality in patients with sustained VT.<sup>
<xref ref-type="bibr" rid="bibr65-1074248413491496">65</xref>
</sup> β-Blockers increase the time to first ICD shock in patients implanted for secondary prevention of sudden death.<sup>
<xref ref-type="bibr" rid="bibr66-1074248413491496">66</xref>
</sup>
</p>
<p>Furthermore, the higher the dose of β-blockers used, the less patients experience VT and the more likely the therapies are successful. In a study of 282 patients with LV dysfunction (EF &lt; 50%) with standard indications for ICD without cardiac resynchronization therapy, the higher the dose of β-blockers, the more successful antitachycardia pacing was in terminating VT.<sup>
<xref ref-type="bibr" rid="bibr41-1074248413491496">41</xref>
</sup>
</p>
</sec>
<sec id="section7-1074248413491496">
<title>Effect of β-Blockers on SCD Prevention in Patients With Heart Failure and Normal EF</title>
<p>Patients with heart failure and normal ejection fraction (HFNEF) represent 50% of patients presenting with heart failure. Despite the normal LVEF, these patients have a prognosis similar to patients with systolic heart failure.<sup>
<xref ref-type="bibr" rid="bibr67-1074248413491496">67</xref>
</sup> However, the exact definition has been evolving, and the best and latest definition was proposed by the European Society of Cardiology in 2007. HFNEF was defined by the presence of signs and symptoms of heart failure, normal LVEF of &gt;50%, LV end-diastolic volume index (LVEDVI) &lt;97 mL/m<sup>2</sup>, signs of diastolic dysfunction on cardiac catheterization or echocardiography.<sup>
<xref ref-type="bibr" rid="bibr68-1074248413491496">68</xref>
</sup> In patients with HFNEF, concentric hypertrophy and high LV mass index to LVEDVI (LVMI/LVEDVI) ratio are present. At the cellular level, there is myocyte hypertrophy, and the cell grows in a transverse direction while keeping the cell length constant.<sup>
<xref ref-type="bibr" rid="bibr69-1074248413491496">69</xref>
</sup> There is also increased deposition of collagen in the interstitial space and loss of connexin 43 expression, which can lead to slow cell-to-cell conduction.<sup>
<xref ref-type="bibr" rid="bibr69-1074248413491496">69</xref>
</sup> It should be noted that most of the patients with HFNEF have history of hypertension, diabetes, and obesity in the absence of hypertrophic cardiomyopathy.<sup>
<xref ref-type="bibr" rid="bibr69-1074248413491496">69</xref>
</sup> Hypertrophied myocytes are more sensitive to ischemia, and ATP-sensitive potassium channels are more likely to open in hypertrophied myocytes compared to normal myocytes. This can lead to prolonged action potential duration, early after depolarizations which can lead to triggered activity and ventricular arrhythmias.<sup>
<xref ref-type="bibr" rid="bibr70-1074248413491496">70</xref>
</sup> Animal models of LV hypertrophy show a lower threshold for VF, especially when myocardial ischemia is present.<sup>
<xref ref-type="bibr" rid="bibr71-1074248413491496">71</xref>
<xref ref-type="bibr" rid="bibr72-1074248413491496"/>
<xref ref-type="bibr" rid="bibr73-1074248413491496"/>–<xref ref-type="bibr" rid="bibr74-1074248413491496">74</xref>
</sup> This could explain the increased mortality and sudden death in patients with coronary artery disease who have LV hypertrophy.<sup>
<xref ref-type="bibr" rid="bibr17-1074248413491496">17</xref>
</sup>
</p>
<p>Despite the effects of β-blockers on LV hypertrophy and the registry data showing mortality benefit with β-blockers in patients with heart failure and normal EF,<sup>
<xref ref-type="bibr" rid="bibr75-1074248413491496">75</xref>,<xref ref-type="bibr" rid="bibr76-1074248413491496">76</xref>
</sup> there is limited clinical trial data available that firmly establish effects on mortality and SCD. The Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure (SENIOR) trial randomized 2128 patients aged ≥70 years with a history of heart failure (recent hospitalization with heart failure or LVEF &lt;35%). The primary end point of death or hospitalization was lower with nebivolol compared to placebo in the overall population, but all-cause mortality was not different between the 2 groups. Only a third of the patients enrolled had LVEF &gt;35%, and even in this subset of patients the overall mortality was not different. The study had several limitations since it was not powered enough to detect difference in mortality in patients with LVEF &gt;35%. Furthermore, there was no strict definition for HFNEF in this trial, which makes it difficult to make any recommendations or generalizations in this patient population.<sup>
<xref ref-type="bibr" rid="bibr77-1074248413491496">77</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section8-1074248413491496">
<title>Renin–Angiotensin–Aldosterone System and SCD Prevention</title>
<sec id="section9-1074248413491496">
<title>Potential Mechanisms of RAAS Inhibitors/Blockers on SCD Prevention</title>
<p>The RAAS is activated during many disease states but especially during myocardial ischemia and heart failure. Renin activates the angiotensin-converting enzyme that converts angiotensin I to angiotensin II. Angiotensin II has 2 receptors, AT<sub>1</sub> and AT<sub>2</sub>. When angiotensin II activates AT<sub>1</sub> receptors, it acts as a potent vasoconstrictor and activates fibroblasts leading to interstitial fibrosis and scar formation. Furthermore, AT<sub>1</sub> receptor stimulation activates the secretion of aldosterone and norepinephrine. All of these factors increase afterload, which increases myocardial oxygen demand and leads to LV hypertrophy.<sup>
<xref ref-type="bibr" rid="bibr78-1074248413491496">78</xref>
</sup> Angiotensin II increases protein synthesis in cardiac myocytes, and it leads to mitogenesis of cardiac fibroblasts. This is a direct effect mediated by AT<sub>1</sub> receptors and is not related to the effects of angiotensin II on blood pressure.<sup>
<xref ref-type="bibr" rid="bibr79-1074248413491496">79</xref>
</sup> Furthermore, angiotensin II induces the angiotensinogen and transforming growth factor β<sub>1</sub> genes, which leads to a positive feedback of the cardiac hypertrophic response.<sup>
<xref ref-type="bibr" rid="bibr79-1074248413491496">79</xref>
</sup>
</p>
<p>Angiotensin II can also be found in the heart tissue and can be synthesized through ACE-independent pathway through the activation of chymase.<sup>
<xref ref-type="bibr" rid="bibr80-1074248413491496">80</xref>
</sup> Chymase has angiotensin-forming capacity that is 20-fold higher than ACE and directly activates metalloproteinases.<sup>
<xref ref-type="bibr" rid="bibr80-1074248413491496">80</xref>,<xref ref-type="bibr" rid="bibr81-1074248413491496">81</xref>
</sup> This is not subject to inhibition by ACE inhibitors. The ACE inhibitors and angiotensin receptor blockers (ARBs) block the uptake of angiotensin II in noninfarcted myocardium through AT<sub>1</sub> receptors. This leads to attenuation of LV remodeling and also increases local angiotensin II production. By blocking AT<sub>1</sub> receptors, the increased angiotensin II activates AT<sub>2</sub> receptors. Activation of AT<sub>2</sub> receptors leads to vasodilatation and inhibits cell growth and mitogen-activated protein kinases that prevent fibrosis.<sup>
<xref ref-type="bibr" rid="bibr82-1074248413491496">82</xref>
</sup> The antihypertrophic effects of RAAS blockade result not only from diminished AT<sub>1</sub> receptor stimulation but also from increased AT<sub>2</sub> receptor stimulation.<sup>
<xref ref-type="bibr" rid="bibr83-1074248413491496">83</xref>
</sup>
</p>
<p>At the cellular level, angiotensin II destabilizes Kv4.3 messenger RNA, a major contributor to outward potassium current.<sup>
<xref ref-type="bibr" rid="bibr84-1074248413491496">84</xref>
</sup> This reduces outward potassium current and leads to prolongation of action potential duration, especially in hypertrophied muscles.<sup>
<xref ref-type="bibr" rid="bibr85-1074248413491496">85</xref>,<xref ref-type="bibr" rid="bibr86-1074248413491496">86</xref>
</sup> These effects are arrhythmogenic and may accelerate progression of heart failure.<sup>
<xref ref-type="bibr" rid="bibr87-1074248413491496">87</xref>
</sup> Angiotensin II also increases L-type calcium channel current and increases the expression of the L-type calcium channel α 1C subunit via a protein kinase C-dependent pathway. This effect is important in the remodeling process observed in atrial fibrillation (AF).<sup>
<xref ref-type="bibr" rid="bibr88-1074248413491496">88</xref>
</sup> Animal models with cardiac-restricted ACE overexpression show marked atrial dilatation, atrial fibrosis, and atrial fibrillation.<sup>
<xref ref-type="bibr" rid="bibr89-1074248413491496">89</xref>
</sup> Several clinical trials showed that ACE inhibitors and ARBs prevent the recurrence of AF, especially after cardioversion and in patients with LV dysfunction, lending more support to their antiarrhythmic effects.<sup>
<xref ref-type="bibr" rid="bibr90-1074248413491496">90</xref>
<xref ref-type="bibr" rid="bibr91-1074248413491496"/>–<xref ref-type="bibr" rid="bibr92-1074248413491496">92</xref>
</sup>
</p>
<p>The ACE inhibitors decrease preload and afterload, which decreases myocardial oxygen demand and LV end-diastolic pressure. They also block angiotensin II production and inhibit the breakdown of bradykinin.<sup>
<xref ref-type="bibr" rid="bibr52-1074248413491496">52</xref>
</sup> Blocking angiotensin II production prevents the progression of ventricular remodeling and reduces ventricular dilatation and fibrosis.<sup>
<xref ref-type="bibr" rid="bibr78-1074248413491496">78</xref>
</sup> The ACE inhibitors result in the reduction in potassium depletion and have several effects on the autonomic nervous system via enhanced baroreflex sensitivity and hemodynamics, which can lead to reduced sympathetic and parasympathetic tone and circulating catecholamines.<sup>
<xref ref-type="bibr" rid="bibr78-1074248413491496">78</xref>
</sup> Angiotensin II could persist despite treatment with ACE inhibitors, since it can be formulated by non-ACE-I-dependent pathways. The ARB can block AT<sub>1</sub> receptors without an increase in bradykinin levels.<sup>
<xref ref-type="bibr" rid="bibr93-1074248413491496">93</xref>
</sup> In the setting of acute MI, pretreatment with angiotensin receptor blockers prevents LV remodeling and blunts the increase in constitutive microtubulin in both the infarcted and the noninfarcted left ventricle.<sup>
<xref ref-type="bibr" rid="bibr94-1074248413491496">94</xref>
</sup>
</p>
<p>Even with the utilization of ACE inhibitors or ARBs, there is no full suppression of aldosterone synthesis. Aldosterone promotes sodium retention, increases potassium secretion in the urine, and activates fibroblasts leading to myocardial and vascular fibrosis.<sup>
<xref ref-type="bibr" rid="bibr95-1074248413491496">95</xref>
</sup> Myocardial fibrosis may increase the risk of ventricular arrhythmias by causing variations in the ventricular conduction times. Aldosterone receptor blockers prevent SCD by controlling potassium loss, blocking aldosterone effect on the formation of collagen, and increasing the myocardial uptake of norepinephrine, which decreases sympathetic activation.<sup>
<xref ref-type="bibr" rid="bibr93-1074248413491496">93</xref>,<xref ref-type="bibr" rid="bibr96-1074248413491496">96</xref>
</sup> Spironolactone decreases the level of serum markers of collagen synthesis at 6 months, which correlates with survival benefit.<sup>
<xref ref-type="bibr" rid="bibr96-1074248413491496">96</xref>
</sup>
</p>
</sec>
<sec id="section10-1074248413491496">
<title>Effect of ACE-I on SCD Prevention in Post-MI Patients and in Patients With Heart Failure</title>
<p>Three post-MI trials, SAVE, Trandolapril Cardiac Evaluation I (TRACE-I), and AIRE, specifically investigated the impact of ACE inhibitors on mortality and morbidity in post-MI patients who have LV dysfunction.</p>
<p>
<italic>Survival and Ventricular Enlargement </italic>was a randomized, double-blind placebo controlled trial that evaluated the use of captopril (n = 1115) versus placebo (n = 1116) in post-MI patients with LVEF ≤40%. Randomization was done 3 to 16 days post-MI. During an average of 42 months, there was an 18% relative risk reduction in all-cause mortality with captopril compared to placebo. However, there was a nonsignificant trend toward lower SCD in patients taking captopril (HR 0.83, 95% CI 0.63-1.8).<sup>
<xref ref-type="bibr" rid="bibr97-1074248413491496">97</xref>
</sup>
</p>
<p>
<italic>Trandolapril Cardiac Evaluation I </italic>was designed to examine whether patients with a recent MI and LV dysfunction would benefit from long-term treatment with ACE inhibitors. A total of 1749 patients 3 to 7 days post-MI with echocardiographic evidence of LV dysfunction (EF ≤ 35%) were randomized to trandolapril (n = 876) or placebo (n = 873). During the follow–up, the relative risk of death from any cause in the trandolapril group versus the placebo group was 0.78 (95% CI 0.67-0.91). The trandolapril group also showed a significant reduction in sudden death versus the placebo group (HR 0.76, 95% CI 0.59-0.98, <italic>P</italic> = .03).<sup>
<xref ref-type="bibr" rid="bibr98-1074248413491496">98</xref>
</sup> The TRACE-I was the first placebo-controlled trial to show a significant reduction in sudden death with the use of the ACE inhibitors.</p>
<p>
<italic>The Acute Infarction Ramipril Efficacy </italic>trial once again looked at the use of ACE-I in the post-MI patient who had clinical or radiological evidence of CHF to receive ramipril (n = 1014) versus placebo (n = 992). After 15 months of follow-up, there was a 27% reduction in the risk of death with ramipril compared to placebo. In this study, ramipril also reduced the risk of sudden death by approximately 30% compared to placebo (<italic>P </italic>= .011).<sup>
<xref ref-type="bibr" rid="bibr99-1074248413491496">99</xref>
</sup>
</p>
<p>A further meta-analysis looked at 15 trials including SAVE, TRACE-I, and AIRE to evaluate the effect of ACE-I on sudden death post-MI. This meta-analysis revealed a significant reduction in the risk of sudden death with an odds ratio of 0.80 (95% CI 0.70-0.92).<sup>
<xref ref-type="bibr" rid="bibr100-1074248413491496">100</xref>
</sup>
</p>
<p>Currently, only 3 trials have reported the results of SCD in patients with systolic heart failure taking ACE-I. <italic>The Cooperative North Scandinavian Enalapril Survival </italic>(CONSENSUS) study was designed to evaluate the effect of enalapril compared to placebo on mortality in patients with severe systolic heart failure (class IV). This study randomized 253 patients to either enalapril (n = 127) or placebo (n = 126) in addition to conventional therapy. The CONSENSUS showed a 40% reduction in mortality after 6 months of treatment and a 27% reduction at the end of the study. The greatest reduction in mortality was in death caused by progression of pump failure.<sup>
<xref ref-type="bibr" rid="bibr101-1074248413491496">101</xref>
</sup>
</p>
<p>
<italic>The Studies of Left Ventricular Dysfunction (SOLVD)-Prevention trial </italic>was designed to determine whether an ACE inhibitor, enalapril, could reduce mortality, the incidence of heart failure, and the rate of hospitalizations in patients with EF ≤ 35%, with mild-to-moderate heart failure (class II or III). Following randomization, patients received double-blind treatment with either placebo (n = 1284) or enalapril (n = 1285). There was a 16% reduction in mortality due to progression of heart failure, but no clear reduction in SCD was noted.<sup>
<xref ref-type="bibr" rid="bibr102-1074248413491496">102</xref>
</sup>
</p>
<p>
<italic>The V-HeFT-II trial</italic> was the first trial to suggest the effect of ACE inhibitors on sudden death in patients with heart failure. This trial compared the effects of enalapril with hydralazine and isosorbide dinitrate on mortality in patients with NYHA class II-III. After randomization, double-blind treatment was instituted with enalapril (n = 403) versus hydralazine/isosorbide dinitrate (n = 401). Interestingly, the mortality curves of the treatment arms separate early after randomization. There was a 28% relative risk reduction with enalapril compared to hydralazine and isosorbide dinitrate (<italic>P</italic> = .016). The overall reduction in mortality associated with enalapril was due to a reduction in the incidence of sudden death.<sup>
<xref ref-type="bibr" rid="bibr103-1074248413491496">103</xref>
</sup>
</p>
</sec>
<sec id="section11-1074248413491496">
<title>Effect of ARBs on SCD Prevention in Patients With CHF</title>
<p>The ARBs were studied extensively and compared or added to ACE inhibitors in the treatment of patients with heart failure (both chronic systolic heart failure and post-MI LV dysfunction). The effects of ARB on mortality in randomized controlled trials in this patient population have been conflicting.</p>
<p>
<italic>The Evaluation of Losartan in the Elderly (</italic>ELITE<italic>)</italic> study is the only ARB trial to demonstrate a reduction in sudden death. This prospective, double-blind, randomized, parallel group controlled clinical trial compared the safety and efficacy in the treatment of CHF with the use of losartan versus captopril. Patients were randomly assigned to losartan (n = 352) versus captopril (n = 370). Follow-up at 48 weeks showed a 45% reduction in all-cause mortality with a relative risk reduction of 36% in the incidence of SCD with losartan compared to captopril.<sup>
<xref ref-type="bibr" rid="bibr104-1074248413491496">104</xref>
</sup>
</p>
<p>The <italic>Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity-Added</italic> (CHARM-ADDED) trial compared candesartan at a mean dose of 32 mg daily or placebo added to captopril in 2548 patients with NYHA class II to III heart failure and mean LVEF of 28%. This trial showed a 15% reduction in total mortality when adding candesartan to captopril, but it did not specifically study SCD.<sup>
<xref ref-type="bibr" rid="bibr105-1074248413491496">105</xref>
</sup> Similarly, the <italic>Valsartan Heart Failure Trial</italic> (Val-HeFT) studied 5010 patients with NYHA class II to III heart failure and mean LVEF of 27%. The study compared valsartan at a dose of 160 mg orally twice daily and placebo added to ACE inhibitors. The study also showed no difference in all-cause mortality but showed a 13% relative risk reduction in cardiovascular morbidity and mortality drive by decreasing heart failure admission. The study did not specifically monitor SCD.<sup>
<xref ref-type="bibr" rid="bibr106-1074248413491496">106</xref>
</sup>
</p>
<p>The <italic>Valsartan in Acute Myocardial Infraction </italic>(VALIANT) trial studied 14 703 patients with post-MI LV dysfunction, mean LVEF of 35%, and Killip class I to II heart failure and compared Valsartan 160 mg orally twice daily versus valsartan 80 mg orally twice daily added to captopril at 50 mg 3 times daily versus captopril at 50 mg orally 3 times daily. There was no difference between the treatment groups when it comes to all-cause mortality or cardiovascular mortality.<sup>
<xref ref-type="bibr" rid="bibr107-1074248413491496">107</xref>
</sup>
</p>
<p>The ELITE<italic> II</italic> was designed to compare the effects of losartan and captopril on all-cause mortality and sudden death or resuscitated cardiac arrest. Similar to ELITE, patients were randomly assigned to losartan (n = 1578) or captopril (n = 1574). After 1.5 years of follow-up, there was no statistical difference in all-cause mortality, sudden death, or resuscitated cardiac arrest (losartan 9% versus captopril 7.3%, <italic>P</italic> = .08) between the 2 groups.<sup>
<xref ref-type="bibr" rid="bibr108-1074248413491496">108</xref>
</sup> It is unclear why the results of ELITE I and ELITE II differed. This could be due to chance, to the smaller numbers, and shorter follow-up period in ELITE I compared to ELITE II. On the other hand, the failure of ELITE II to show superiority of losartan over captopril could be due to the low dose (50 mg) of losartan used. The HEAAL trial showed that a higher dose of losartan (150 mgs once daily) is superior to low-dose losartan (50 mg once daily) in decreasing mortality and hospitalization in patients with systolic heart failure.<sup>
<xref ref-type="bibr" rid="bibr109-1074248413491496">109</xref>
</sup> It is also possible that these medications would have shown a reduction in overall mortality and sudden death when compared to placebo and not ACE-I, since both will block the effects of angiotensin II. The CHARM-alternative trial showed a reduction in cardiovascular mortality and hospitalization when using candesartan compared to placebo in patients intolerant to ACE-I.<sup>
<xref ref-type="bibr" rid="bibr110-1074248413491496">110</xref>
</sup> Currently, there is no clear evidence that ARBs have a direct effect on SCD prevention, and they currently remain second line in patients with systolic heart failure after maximizing the treatment with ACE inhibitors or if the patient is intolerant to ACE inhibitors.<sup>
<xref ref-type="bibr" rid="bibr111-1074248413491496">111</xref>
</sup>
</p>
</sec>
<sec id="section12-1074248413491496">
<title>Effect of Aldosterone Antagonists on SCD Prevention in Post-MI Patients and in Patients With CHF</title>
<p>
<italic>The Randomized Aldactone Evaluation Study (RALES)</italic> is a randomized, double-blind placebo controlled trial that compared spironolactone (n = 822) versus placebo (n = 841) in patients with severe heart failure. Patients enrolled had class III or IV heart failure and were being treated with an ACE inhibitor, loop diuretic, and had an EF ≤ 35%. This trial was ended prematurely when analysis found that spironolactone demonstrated a 31% reduction in cardiac death. This reduction was due to a 36% in death related to progressive heart failure and a 29% reduction in SCD.<sup>
<xref ref-type="bibr" rid="bibr112-1074248413491496">112</xref>
</sup>
</p>
<p>
<italic>The Eplerenone Post Myocardial Heart Failure Efficacy and Survival Study (EPHESUS)</italic> was conducted to evaluate the effect of aldosterone blocker, eplerenone on morbidity, and mortality among patients with acute MI complicated by LV dysfunction and heart failure. In this double-blind, placebo-controlled study, patients were randomly assigned to eplerenone (n = 3313) versus placebo (n = 3319) in addition to optimal medical therapy. eplerenone demonstrated a reduction in death from cardiovascular causes or hospitalization for cardiovascular events (relative risk 0.83; 95% CI 0.72-0.94; <italic>P</italic> = .005). There was also a reduction in sudden death from cardiac causes (relative risk 0.79; 95% CI 0.64-0.97; <italic>P</italic> = .03).<sup><xref ref-type="bibr" rid="bibr113-1074248413491496">113</xref></sup>
</p>
<p>Although there is a clear benefit of aldosterone blockers in the setting of heart failure and post-MI patients., this does not come without a price. Most of the patients with heart failure will have renal impairment, and if care is not taken to follow the kidney function and the potassium levels, hyperkalemia and arrhythmic death could occur obviating the benefit of these medications. In the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial, there was a 1.4 increase in total mortality and cardiovascular mortality, driven mainly by an increase in SCD (HR 2.0, 95% CI 1.3-3.0, <italic>P</italic> = .001).<sup>
<xref ref-type="bibr" rid="bibr114-1074248413491496">114</xref>
</sup> There was a high prevalence of renal dysfunction in this study, and 45% of the patients were on aldosterone blockers, mainly spironolactone. This was a post hoc analysis of the trial, and care should be taken in extrapolating the data. Although the randomized studies show a clear benefit of aldosterone blockers in decreasing all-cause mortality and SCD, care should be taken to follow the kidney function and monitor potassium levels.</p>
</sec>
<sec id="section13-1074248413491496">
<title>Renin–Angiotensin–Aldosterone System Inhibitors/Blockers in Patients With Heart Failure and Normal EF</title>
<p>The presence of myocyte hypertrophy and collagen deposition in patients with HFNEF justifies the use of renin–angiotensin–aldosterone inhibitors/blockers from a mechanistic stand point. In animal models, treatment with captopril leads to regression of LV hypertrophy and reversal of proarrhythmic properties of the myocardium.<sup>
<xref ref-type="bibr" rid="bibr71-1074248413491496">71</xref>
</sup> The losartan Intervention For Endpoint reduction in Hypertension (LIFE) study showed that losartan leads to regression of LV hypertrophy on the electrocardiogram, which was associated with reduction in SCD.<sup>
<xref ref-type="bibr" rid="bibr115-1074248413491496">115</xref>
</sup>
</p>
<p>The Perindopril in elderly people with chronic heart failure (PEP-CHF) trial was the first trial to examine the use of ACE-I in patients with HFNEF. Patients older than 70 years of age were enrolled if they had LVEF &gt;40%, evidence of LV hypertrophy, and abnormal filling pressures on mitral inflow velocity Doppler as well as a diagnosis of HF. There was no difference in mortality in heart failure or hospitalizations. The trial has the same shortcomings the SENIOR trial had in its design, since the accurate definition of HFNEF had to satisfy 3 of 9 criteria, one of which is MI. As a result, 40% of the patients had a history of coronary artery disease and eccentric hypertrophy as opposed to concentric hypertrophy.<sup>
<xref ref-type="bibr" rid="bibr116-1074248413491496">116</xref>
</sup>
</p>
<p>The CHARM-preserved trial compared candsartan to placebo in patients with HF and normal LVEF. However, there was no significant effect of candesartan on cardiovascular mortality.<sup>
<xref ref-type="bibr" rid="bibr117-1074248413491496">117</xref>
</sup> The CHARM preserved also enrolled may patients who had history of MI (45% of the patients enrolled had history of prior MI and coronary artery disease). This confounds the results, since these patients were found to have eccentric hypertrophy. The Candesartan in Heart Failure Reduction in Mortality Echocardiographic Substudy (CHARMES)<sup>
<xref ref-type="bibr" rid="bibr118-1074248413491496">118</xref>
</sup> showed that 66% of the patients had LVMI of 111 g/m<sup>2</sup>, which is in the normal range.<sup>
<xref ref-type="bibr" rid="bibr119-1074248413491496">119</xref>
</sup>
</p>
<p>Finally, the Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) trial randomized 4128 patients to irbesartan versus placebo. Most of the patients had normal LVEF. Only 24% of these patients enrolled had history of coronary artery disease. There was no difference in mortality or hospitalization in patients taking irbesartan compared to placebo.<sup>
<xref ref-type="bibr" rid="bibr120-1074248413491496">120</xref>
</sup>
</p>
<p>Overall, patients enrolled in the above trials were mostly selected based on the presence of normal LVEF and heart failure symptoms, but the cutoff of LVEF varied and the presence of diastolic dysfunction was mostly based on mitral inflow velocity that changes with age and other conditions. The high prevalence of coronary artery disease was found to be responsible for enrolling patients with eccentric as opposed to concentric hypertrophy and remodeling. The new ESC guidelines for diagnosing HFNEF offer a better definition of HFNEF that was not present during the design of these trials.<sup>
<xref ref-type="bibr" rid="bibr68-1074248413491496">68</xref>
</sup> This offers huge opportunities for further clinical studies in this patient population.</p>
</sec>
</sec>
<sec id="section14-1074248413491496">
<title>Statins (3-Hydroxy-3-Methylglutaryl Coenzyme-A Reductase Inhibitors) and SCD Prevention</title>
<sec id="section15-1074248413491496">
<title>Potential Mechanisms of 3 Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors on SCD Prevention</title>
<p>Statins (3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors) have been shown to decrease cardiovascular morbidity and mortality in both primary and secondary prevention trials.<sup><xref ref-type="bibr" rid="bibr121-1074248413491496">121</xref><xref ref-type="bibr" rid="bibr122-1074248413491496"/>–<xref ref-type="bibr" rid="bibr123-1074248413491496">123</xref>
</sup> Statins are known to stabilize the plaque and to even promote plaque regression.<sup>
<xref ref-type="bibr" rid="bibr124-1074248413491496">124</xref>
</sup>This stabilization improves myocardial perfusion and oxidative stress and reduces the risk of plaque rupture.<sup>
<xref ref-type="bibr" rid="bibr125-1074248413491496">125</xref>
</sup> This leads to decreased ischemic events and arrhythmic events, since even small areas of ischemia can promote reentry, induce ventricular arrhythmias, and lead to SCD. Statins improve endothelial function by increasing nitric oxide production from endothelial cells, and they reduce ischemia-mediated oxidative stress and intracellular calcium overload.<sup>
<xref ref-type="bibr" rid="bibr126-1074248413491496">126</xref>,<xref ref-type="bibr" rid="bibr127-1074248413491496">127</xref>
</sup> They also have anti-inflammatory actions, reduce C-reactive protein, and decrease endothelin-1 secretion.<sup>
<xref ref-type="bibr" rid="bibr128-1074248413491496">128</xref>
</sup> All these effects will decrease myocardial ischemia, limit myocardial injury, and prevent myocyte hypertrophy.<sup>
<xref ref-type="bibr" rid="bibr129-1074248413491496">129</xref>,<xref ref-type="bibr" rid="bibr130-1074248413491496">130</xref>
</sup> Statins have been shown to improve LVEF in patients with dilated cardiomyopathy even after short duration of therapy.<sup>
<xref ref-type="bibr" rid="bibr131-1074248413491496">131</xref>,<xref ref-type="bibr" rid="bibr132-1074248413491496">132</xref>
</sup> Pravastatin was shown to increase contractile function of hibernating myocardium in a canine model by increasing myocyte cell proliferation and reentry to the growth phase of the cardiac cell cycle.<sup>
<xref ref-type="bibr" rid="bibr133-1074248413491496">133</xref>
</sup> Furthermore, statins also decrease QT dispersion, improve autonomic tone and heart rate variability, and modulate ion channels independent of their lipid-lowering effects.<sup>
<xref ref-type="bibr" rid="bibr134-1074248413491496">134</xref>,<xref ref-type="bibr" rid="bibr135-1074248413491496">135</xref>
</sup> These “pleiotropic” properties may account for their effect on reducing arrhythmic death in both ischemic and nonischemic cardiomyopathy.</p>
</sec>
<sec id="section16-1074248413491496">
<title>Effect of Statin Therapy on Shock Burden and SCD in Post-MI Patients and in Patients With CHF</title>
<p>Statins are widely accepted as preventing coronary heart disease death and MI; however, their effect on SCD prevention is unclear. Randomized Trials in post-MI patients showed the benefits of statins on overall mortality but failed to show benefit on SCD prevention.<sup><xref ref-type="bibr" rid="bibr121-1074248413491496">121</xref>,<xref ref-type="bibr" rid="bibr136-1074248413491496">136</xref>,<xref ref-type="bibr" rid="bibr137-1074248413491496">137</xref>
</sup> However, observational data from hospitalized patients with MI showed that early statin administration (within 24 hours) of an acute MI led to a decrease in the incidence of VT/VF.<sup>
<xref ref-type="bibr" rid="bibr138-1074248413491496">138</xref>
</sup> Statins appear to decrease appropriate shocks in patients who have ICDs whether or not they received them for primary or secondary prevention of SCD. In a subanalysis of AVID trial, a secondary prevention trial that compared antiarrhythmic drugs to ICDs in patients who survived a cardiac arrest, patients who received statins had a lower risk of ventricular arrhythmias compared to those who are not on statins.<sup>
<xref ref-type="bibr" rid="bibr139-1074248413491496">139</xref>
</sup> This was also demonstrated in the MADIT-II. Post hoc analysis of MADIT-II showed that patients receiving statin therapy &gt;90% of the time had a significantly reduced cumulative rate of ICD therapy for VT/VF or cardiac death.<sup>
<xref ref-type="bibr" rid="bibr140-1074248413491496">140</xref>
</sup> Subsequently, an analysis of SCD-HeFT trial data was undertaken to evaluate the impact of statin use in heart failure. The SCD-HeFT studied 2521 patients with functional class II and III heart failure having LVEFs ≤35%. The cause of CHF was ischemic in 52% of the study patients. Statin use was reported in 965 (38%) of 2521 patients at baseline and 1187 (47%) at last follow-up with the median time to follow-up of 45.5 months. This analysis revealed that mortality reduction related to statin therapy (HR = 0.70, 95% CI 0.58-0.83) was identical in both ischemic and nonischemic cardiomyopathy (HR 0.69 vs 0.67, respectively).<sup>
<xref ref-type="bibr" rid="bibr141-1074248413491496">141</xref>
</sup>
</p>
<p>Statins decrease the risk of arrhythmic death in patients with nonischemic cardiomyopathy. The Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial enrolled 458 patients with nonischemic cardiomyopathy to receive a defibrillator versus optimal medical therapy. More than 90% of the patients were taking β-blockers and ACE inhibitors. Statin therapy was not randomized in this trial. There was a 78% relative risk reduction of death in patients taking statins (n = 110) versus those not on statins (n = 348).<sup>
<xref ref-type="bibr" rid="bibr142-1074248413491496">142</xref>
</sup> The same observation was seen in MADIT with cardiac resynchronization therapy (MADIT-CRT) trial. Of the 821 with nonischemic cardiomyopathy enrolled in MADIT-CRT, there were 499 patients taking statins. Multivariate analysis showed that time-dependent statin therapy was independently associated with a 77% reduction in the risk of VT/VF or death (<italic>P</italic> &lt; .001) and with a 46% reduction in the risk of appropriate implantable cardioverter defibrillator shocks (<italic>P</italic> = .01) regardless if the patient received a cardiac resynchronization device or if they were enrolled to receive a defibrillator only.<sup>
<xref ref-type="bibr" rid="bibr143-1074248413491496">143</xref>
</sup>
</p>
<p>Two major clinical trials on the use of rosuvastatin in patients with systolic heart failure failed to show mortality benefit. The first is the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) trial that studied 5011 patients older than 60 years of age with NYHA class II, III, and IV ischemic heart failure. Patients were randomized to receive 10 mg of Rosuvastatin versus placebo. Despite 45% reduction in low-density lipoprotein cholesterol and 37% reduction in high-sensitivity C-reactive protein, there was no difference in the primary outcome of cardiovascular death or death from any cause. Treatment with rosuvastatin led to a decrease in hospitalization and was well tolerated by this population of patients.<sup>
<xref ref-type="bibr" rid="bibr144-1074248413491496">144</xref>
</sup> The lack of benefit could be due to chance, short follow–up, or age of the population studied. The GISSI-HF trial randomized patients with NYHA class II-IV heart failure irrespective of cause or LVEF to 10 mg of rosuvastatin versus placebo. There was no difference in mortality in the patients assigned to rosuvastatin (2285 patients) compared to patients assigned to placebo (2289 patients) after 4 years of follow-up (HR 1.00, 95% CI of 0.89-1.12, <italic>P</italic> = .94). There was also no difference in hospitalization between the 2 groups of patients.<sup>
<xref ref-type="bibr" rid="bibr145-1074248413491496">145</xref>
</sup>
</p>
<p>Why did the post hoc analysis from MADIT-II, SCD-HeFT and MADIT-CRT differ from the results of CORONA and GISSI-HF trials? One possibility is related to the limitations of post hoc analysis and possibility of bias and chance. Another is related to the type of statin used by the patients. Although CORONA and GISSI-HF studied rosuvastatin, patients in MADIT-CRT and SCD-HeFT were taking different types of statins at different doses. Furthermore, patients in MADIT-CRT had mild heart failure (NYHA class I and II) compared to the majority of patients in CORONA and GISSI-HF who had moderate to severe HF (mostly classes III and IV). Whether different statins have different effects in patients with heart failure needs to be further clarified. Atorvastatin and simvastatin were shown to improve LVEF in patients with dilated cardiomyopathy.<sup>
<xref ref-type="bibr" rid="bibr82-1074248413491496">82</xref>,<xref ref-type="bibr" rid="bibr83-1074248413491496">83</xref>
</sup> Finally, pravastatin was shown in an animal model to increase contractile performance of hibernating myocardium by increasing myocyte cell cycle reentry and proliferation.<sup>
<xref ref-type="bibr" rid="bibr133-1074248413491496">133</xref>
</sup> It has been shown that β-blockers are more effective in patients who have more viable myocardium and are less effective when the scar is &gt;75% of wall thickness.<sup>
<xref ref-type="bibr" rid="bibr37-1074248413491496">37</xref>
</sup> Whether this is also true in patients taking statins is another area that needs to be explored. Taking all the available data together, statins appear to reduce the frequency of ICD shocks even in patients taking β-blockers and ACE-I. They appear to be useful in patients with systolic heart failure who have received a defibrillator for primary or secondary prevention and are generally well tolerated. More randomized trials utilizing different statins at different doses are needed to clarify the effects of statins on sudden death in patient with mild, moderate, and severe heart failure.</p>
</sec>
</sec>
</sec>
<sec id="section17-1074248413491496">
<title>Conclusions and Future Directions</title>
<p>The SCD remains a challenge for health providers and policy makers. Whether more stringent guidelines for prevention and screening will be applied is balanced by the enormous costs, this will place on the health care system. In order to identify the groups at risk of SCD, there must first be a standardization of the definition. The worldly variation in the definition of SCD of 1 hour from onset of symptoms to 24 hours not only affects epidemiological data but also alters clinical trial outcomes when evaluating the effectiveness of treatment and prevention options.<sup>
<xref ref-type="bibr" rid="bibr6-1074248413491496">6</xref>
</sup>
</p>
<p>Currently, antiarrhythmic medications have failed to show any benefit of SCD prevention, although traditional heart failure medications have been shown to decrease total mortality, SCD, and defibrillator shocks. They are used only in a small subset of patients at risk of SCD, since most of the patients who have SCD have it as a first presentation and do not have systolic heart failure.<sup>
<xref ref-type="bibr" rid="bibr3-1074248413491496">3</xref>,<xref ref-type="bibr" rid="bibr4-1074248413491496">4</xref>
</sup> A focus on coronary artery disease prevention is warranted given the fact that coronary artery disease is present in &gt;50% of patients older than 35 years of age who died suddenly and underwent autopsy.<sup>
<xref ref-type="bibr" rid="bibr3-1074248413491496">3</xref>
</sup> But even screening and prevention carries challenges. Intravascular ultrasound studies in hearts of cardiac transplant donors showed significant atherosclerotic plaque even in individuals younger than 20 years.<sup>
<xref ref-type="bibr" rid="bibr146-1074248413491496">146</xref>
</sup> For primary prevention of coronary artery disease, most of the primary prevention algorithms will not initiate statin therapy till the patient is in his or her 50s, even if he or she has multiple risk factors.<sup>
<xref ref-type="bibr" rid="bibr147-1074248413491496">147</xref>
</sup> The cost of starting this treatment is also enormous, especially if it is started on a global scale at a young age, and it is not without side effects. Genetic studies to identify patients at risk of SCD are important and are still under development. Well-designed clinical trials that target patients with heart failure and normal EF are needed to treat this large population of patients that are at risk. Identifying other parameters that can help risk stratify the patients at risk of sudden death other than the LVEF is another area that needs further studies. Preventing SCD is definitely a challenge for the 21st century clinician and might remain so for the near future.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-1074248413491496">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-1074248413491496">
<label>Funding</label>
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1074248413491496">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Escobedo</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Zack</surname>
<given-names>MM</given-names>
</name>
</person-group>. <article-title>Comparison of sudden and nonsudden coronary deaths in the united states</article-title>. <source>Circulation</source>. <year>1996</year>;<volume>93</volume>(<issue>11</issue>):<fpage>2033</fpage>–<lpage>2036</lpage>.</citation>
</ref>
<ref id="bibr2-1074248413491496">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>ZJ</given-names>
</name>
<name>
<surname>Croft</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Giles</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Mensah</surname>
<given-names>GA</given-names>
</name>
</person-group>. <article-title>Sudden cardiac death in the United States, 1989 to 1998</article-title>. <source>Circulation</source>. <year>2001</year>;<volume>104</volume>(<issue>18</issue>):<fpage>2158</fpage>–<lpage>2163</lpage>.</citation>
</ref>
<ref id="bibr3-1074248413491496">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chugh</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Jui</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gunson</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community</article-title>. <source>J Am Coll Cardiol</source>. <year>2004</year>;<volume>44</volume>(<issue>6</issue>):<fpage>1268</fpage>–<lpage>1275</lpage>.</citation>
</ref>
<ref id="bibr4-1074248413491496">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cobb</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Fahrenbruch</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Olsufka</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Copass</surname>
<given-names>MK</given-names>
</name>
</person-group>. <article-title>Changing incidence of out-of-hospital ventricular fibrillation, 1980-2000</article-title>. <source>JAMA</source>. <year>2002</year>;<volume>288</volume>(<issue>23</issue>):<fpage>3008</fpage>–<lpage>3013</lpage>.</citation>
</ref>
<ref id="bibr5-1074248413491496">
<label>5</label>
<citation citation-type="journal">
<collab collab-type="author">European Heart Rhythm A; Heart Rhythm Society</collab>, <person-group person-group-type="author">
<name>
<surname>Zipes</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Camm</surname>
<given-names>AJ</given-names>
</name>
<etal/>
</person-group>. <article-title>ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American college of cardiology/American heart association task force and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death)</article-title>. <source>J Am Coll Cardiol</source>. <year>2006</year>;<volume>48</volume>(<issue>5</issue>):<fpage>e247</fpage>–<lpage>e346</lpage>.</citation>
</ref>
<ref id="bibr6-1074248413491496">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kong</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Fonarow</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>ED</given-names>
</name>
<etal/>
</person-group>. <article-title>Systematic review of the incidence of sudden cardiac death in the united states</article-title>. <source>J Am Coll Cardiol</source>. <year>2011</year>;<volume>57</volume>(<issue>7</issue>):<fpage>794</fpage>–<lpage>801</lpage>.</citation>
</ref>
<ref id="bibr7-1074248413491496">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Every</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Parsons</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hlatky</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>. <article-title>Use and accuracy of state death certificates for classification of sudden cardiac deaths in high-risk populations</article-title>. <source>Am Heart J</source>. <year>1997</year>;<volume>134</volume>(<issue>6</issue>):<fpage>1129</fpage>–<lpage>1132</lpage>.</citation>
</ref>
<ref id="bibr8-1074248413491496">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Engel</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Strauchen</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Chiazze</surname>
<given-names>L</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Heid</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Accuracy of death certification in an autopsied population with specific attention to malignant neoplasms and vascular diseases</article-title>. <source>Am J Epidemiol</source>. <year>1980</year>;<volume>111</volume>(<issue>1</issue>):<fpage>99</fpage>–<lpage>112</lpage>.</citation>
</ref>
<ref id="bibr9-1074248413491496">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Modelmog</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rahlenbeck</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Trichopoulos</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Accuracy of death certificates: a population-based, complete-coverage, one-year autopsy study in east Germany</article-title>. <source>Cancer Causes &amp; Control</source>. <year>1992</year>;<volume>3</volume>(<issue>6</issue>):<fpage>541</fpage>–<lpage>546</lpage>.</citation>
</ref>
<ref id="bibr10-1074248413491496">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roulson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Benbow</surname>
<given-names>EW</given-names>
</name>
<name>
<surname>Hasleton</surname>
<given-names>PS</given-names>
</name>
</person-group>. <article-title>Discrepancies between clinical and autopsy diagnosis and the value of post mortem histology; a meta-analysis and review</article-title>. <source>Histopathology</source>. <year>2005</year>;<volume>47</volume>(<issue>6</issue>):<fpage>551</fpage>–<lpage>559</lpage>.</citation>
</ref>
<ref id="bibr11-1074248413491496">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nichol</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Callaway</surname>
<given-names>CW</given-names>
</name>
<etal/>
</person-group>. <article-title>Regional variation in out-of-hospital cardiac arrest incidence and outcome</article-title>. <source>JAMA</source>. <year>2008</year>;<volume>300</volume>(<issue>12</issue>):<fpage>1423</fpage>–<lpage>1431</lpage>.</citation>
</ref>
<ref id="bibr12-1074248413491496">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bardy</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Mark</surname>
<given-names>DB</given-names>
</name>
<etal/>
</person-group>. <article-title>Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure</article-title>. <source>N Engl J Med</source>. <year>2005</year>;<volume>352</volume>(<issue>3</issue>):<fpage>225</fpage>–<lpage>237</lpage>.</citation>
</ref>
<ref id="bibr13-1074248413491496">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buxton</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Hafley</surname>
<given-names>GE</given-names>
</name>
<etal/>
</person-group>. <article-title>Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study</article-title>. <source>J Am Coll Cardiol</source>. <year>2007</year>;<volume>50</volume>(<issue>12</issue>):<fpage>1150</fpage>–<lpage>1157</lpage>.</citation>
</ref>
<ref id="bibr14-1074248413491496">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stecker</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Vickers</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Waltz</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon sudden unexpected death study</article-title>. <source>J Am Coll Cardiol</source>. <year>2006</year>;<volume>47</volume>(<issue>6</issue>):<fpage>1161</fpage>–<lpage>1166</lpage>.</citation>
</ref>
<ref id="bibr15-1074248413491496">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cabassi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vinci</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Calzolari</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bruschi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Borghetti</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Regional sympathetic activity in pre-hypertensive phase of spontaneously hypertensive rats</article-title>. <source>Life Sci</source>. <year>1998</year>;<volume>62</volume>(<issue>12</issue>):<fpage>1111</fpage>–<lpage>1118</lpage>.</citation>
</ref>
<ref id="bibr16-1074248413491496">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quinones</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Kopelen</surname>
<given-names>HA</given-names>
</name>
<etal/>
</person-group>. <article-title>Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: Significance of left ventricular hypertrophy. Studies of left ventricular dysfunction</article-title>. <source>J Am Coll Cardiol</source>. <year>2000</year>;<volume>35</volume>(<issue>5</issue>):<fpage>1237</fpage>–<lpage>1244</lpage>.</citation>
</ref>
<ref id="bibr17-1074248413491496">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turakhia</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Schiller</surname>
<given-names>NB</given-names>
</name>
<name>
<surname>Whooley</surname>
<given-names>MA</given-names>
</name>
</person-group>. <article-title>Prognostic significance of increased left ventricular mass index to mortality and sudden death in patients with stable coronary heart disease (from the heart and soul study)</article-title>. <source>Am J Cardiol</source>. <year>2008</year>;<volume>102</volume>(<issue>9</issue>):<fpage>1131</fpage>–<lpage>1135</lpage>.</citation>
</ref>
<ref id="bibr18-1074248413491496">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Packer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fowler</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Roecker</surname>
<given-names>EB</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study</article-title>. <source>Circulation</source>. <year>2002</year>;<volume>106</volume>(<issue>17</issue>):<fpage>2194</fpage>–<lpage>2199</lpage>.</citation>
</ref>
<ref id="bibr19-1074248413491496">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindenfeld</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Saxon</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association Class IV Heart Failure</article-title>. <source>Circulation</source>. <year>2007</year>;<volume>115</volume>(<issue>2</issue>):<fpage>204</fpage>–<lpage>212</lpage>.</citation>
</ref>
<ref id="bibr20-1074248413491496">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rouleau</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shenasa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Champlain</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Predictors of survival and sudden death in patients with stable severe congestive heart failure due to ischemic and nonischemic causes: a prospective long term study of 200 patients</article-title>. <source>Can J Cardiol</source>. <year>1990</year>;<volume>6</volume>(<issue>10</issue>):<fpage>453</fpage>–<lpage>460</lpage>.</citation>
</ref>
<ref id="bibr21-1074248413491496">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carmeliet</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Cardiac ionic currents and acute ischemia: from channels to arrhythmias</article-title>. <source>Physiol Rev</source>. <year>1999</year>;<volume>79</volume>(<issue>3</issue>):<fpage>917</fpage>–<lpage>1017</lpage>.</citation>
</ref>
<ref id="bibr22-1074248413491496">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kleber</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Rudy</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>Basic mechanisms of cardiac impulse propagation and associated arrhythmias</article-title>. <source>Physiol Rev</source>. <year>2004</year>;<volume>84</volume>(<issue>2</issue>):<fpage>431</fpage>–<lpage>488</lpage>.</citation>
</ref>
<ref id="bibr23-1074248413491496">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reiken</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wehrens</surname>
<given-names>XH</given-names>
</name>
<name>
<surname>Vest</surname>
<given-names>JA</given-names>
</name>
<etal/>
</person-group>. <article-title>Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure</article-title>. <source>Circulation</source>. <year>2003</year>;<volume>107</volume>(<issue>19</issue>):<fpage>2459</fpage>–<lpage>2466</lpage>.</citation>
</ref>
<ref id="bibr24-1074248413491496">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pereira</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lao</surname>
<given-names>DH</given-names>
</name>
<etal/>
</person-group>. <article-title>Epac2 mediates cardiac beta1-adrenergic-dependent sarcoplasmic reticulum Ca<sup>2+</sup> leak and arrhythmia</article-title>. <source>Circulation</source>. <year>2013</year>;<volume>127</volume>(<issue>8</issue>):<fpage>913</fpage>–<lpage>922</lpage>.</citation>
</ref>
<ref id="bibr25-1074248413491496">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomaselli</surname>
<given-names>GF</given-names>
</name>
<name>
<surname>Zipes</surname>
<given-names>DP</given-names>
</name>
</person-group>. <article-title>What causes sudden death in heart failure?</article-title> <source>Circ Res</source>. <year>2004</year>;<volume>95</volume>(<issue>8</issue>):<fpage>754</fpage>–<lpage>763</lpage>.</citation>
</ref>
<ref id="bibr26-1074248413491496">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huikuri</surname>
<given-names>HV</given-names>
</name>
<name>
<surname>Castellanos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Myerburg</surname>
<given-names>RJ</given-names>
</name>
</person-group>. <article-title>Sudden death due to cardiac arrhythmias</article-title>. <source>N Engl J Med</source>. <year>2001</year>;<volume>345</volume>(<issue>20</issue>):<fpage>1473</fpage>–<lpage>1482</lpage>.</citation>
</ref>
<ref id="bibr27-1074248413491496">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mann</surname>
<given-names>DL</given-names>
</name>
</person-group>. <article-title>Basic mechanisms of disease progression in the failing heart: the role of excessive adrenergic drive</article-title>. <source>Prog Cardiovasc Dis</source>. <year>1998</year>;<volume>41</volume>(<issue>1 suppl 1</issue>):<fpage>1</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr28-1074248413491496">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chidsey</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Sonnenblick</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Morrow</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Braunwald</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Norepinephrine stores and contractile force of papillary muscle from the failing human heart</article-title>. <source>Circulation</source>. <year>1966</year>;<volume>33</volume>(<issue>1</issue>):<fpage>43</fpage>–<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr29-1074248413491496">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hasegawa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Iwai-Kanai</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sasayama</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Neurohormonal regulation of myocardial cell apoptosis during the development of heart failure</article-title>. <source>J Cell Physiol</source>. <year>2001</year>;<volume>186</volume>(<issue>1</issue>):<fpage>11</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr30-1074248413491496">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Francis</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Benedict</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Johnstone</surname>
<given-names>DE</given-names>
</name>
<etal/>
</person-group>. <article-title>Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD)</article-title>. <source>Circulation</source>. <year>1990</year>;<volume>82</volume>(<issue>5</issue>):<fpage>1724</fpage>–<lpage>1729</lpage>.</citation>
</ref>
<ref id="bibr31-1074248413491496">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calvert</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Condit</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Aragon</surname>
<given-names>JP</given-names>
</name>
<etal/>
</person-group>. <article-title>Exercise protects against myocardial ischemia-reperfusion injury via stimulation of beta(3)-adrenergic receptors and increased nitric oxide signaling: role of nitrite and nitrosothiols</article-title>. <source>Circ Res</source>. <year>2011</year>;<volume>108</volume>(<issue>12</issue>):<fpage>1448</fpage>–<lpage>1458</lpage>.</citation>
</ref>
<ref id="bibr32-1074248413491496">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gorre</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Vandekerckhove</surname>
<given-names>H.</given-names>
</name>
</person-group> <article-title>Beta-blockers: Focus on mechanism of action. Which beta-blocker, when and why?</article-title> <source>Acta Cardiol</source>. <year>2012</year>;<volume>65</volume>(<issue>5</issue>):<fpage>565</fpage>–<lpage>570</lpage>.</citation>
</ref>
<ref id="bibr33-1074248413491496">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swedberg</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Viquerat</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rouleau</surname>
<given-names>JL</given-names>
</name>
<etal/>
</person-group>. <article-title>Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure</article-title>. <source>Am J Cardiol</source>. <year>1984</year>;<volume>54</volume>(<issue>7</issue>):<fpage>783</fpage>–<lpage>786</lpage>.</citation>
</ref>
<ref id="bibr34-1074248413491496">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gorre</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Vandekerckhove</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Beta-blockers: focus on mechanism of action. Which beta-blocker, when and why?</article-title> <source>Acta Cardiol</source>. <year>2010</year>;<volume>65</volume>(<issue>5</issue>):<fpage>565</fpage>–<lpage>570</lpage>.</citation>
</ref>
<ref id="bibr35-1074248413491496">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilbert</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Olsen</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart</article-title>. <source>Circulation</source>. <year>1996</year>;<volume>94</volume>(<issue>11</issue>):<fpage>2817</fpage>–<lpage>2825</lpage>.</citation>
</ref>
<ref id="bibr36-1074248413491496">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Cigarroa</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Marcoux</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade</article-title>. <source>J Am Coll Cardiol</source>. <year>1995</year>;<volume>25</volume>(<issue>5</issue>):<fpage>1154</fpage>–<lpage>1161</lpage>.</citation>
</ref>
<ref id="bibr37-1074248413491496">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bello</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Farah</surname>
<given-names>GM</given-names>
</name>
<etal/>
</person-group>. <article-title>Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy</article-title>. <source>Circulation</source>. <year>2003</year>;<volume>108</volume>(<issue>16</issue>):<fpage>1945</fpage>–<lpage>1953</lpage>.</citation>
</ref>
<ref id="bibr38-1074248413491496">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yaoita</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sakabe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Maehara</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Maruyama</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats</article-title>. <source>Circulation</source>. <year>2002</year>;<volume>105</volume>(<issue>8</issue>):<fpage>975</fpage>–<lpage>980</lpage>.</citation>
</ref>
<ref id="bibr39-1074248413491496">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilber</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Zareba</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>WJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Time dependence of mortality risk and defibrillator benefit after myocardial infarction</article-title>. <source>Circulation</source>. <year>2004</year>;<volume>109</volume>(<issue>9</issue>):<fpage>1082</fpage>–<lpage>1084</lpage>.</citation>
</ref>
<ref id="bibr40-1074248413491496">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seidl</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hauer</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Schwick</surname>
<given-names>NG</given-names>
</name>
<etal/>
</person-group>. <article-title>Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter/defibrillator</article-title>. <source>Am J Cardiol</source>. <year>1998</year>;<volume>82</volume>(<issue>6</issue>):<fpage>744</fpage>–<lpage>748</lpage>.</citation>
</ref>
<ref id="bibr41-1074248413491496">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jimenez-Candil</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hernandez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Influence of beta-blocker therapy on antitachycardia pacing effectiveness for monomorphic ventricular tachycardias occurring in implantable cardioverter-defibrillator patients: a dose-dependent effect</article-title>. <source>Europace</source>. <year>2012</year>;<volume>12</volume>(<issue>9</issue>):<fpage>1231</fpage>–<lpage>1238</lpage>.</citation>
</ref>
<ref id="bibr42-1074248413491496">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snow</surname>
<given-names>PJ</given-names>
</name>
</person-group>. <article-title>Effect of propranolol in myocardial infarction</article-title>. <source>Lancet</source>. <year>1965</year>;<volume>2</volume>(<issue>7412</issue>):<fpage>551</fpage>–<lpage>553</lpage>.</citation>
</ref>
<ref id="bibr43-1074248413491496">
<label>43</label>
<citation citation-type="journal">
<collab collab-type="author">Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction</collab>. <source>N Engl J Med</source>. <year>1981</year>;<volume>304</volume>(<issue>14</issue>):<fpage>801</fpage>–<lpage>807</lpage>.</citation>
</ref>
<ref id="bibr44-1074248413491496">
<label>44</label>
<citation citation-type="journal">
<collab collab-type="author">A randomized trial of propranolol in patients with acute myocardial infarction. II</collab>. <article-title>Morbidity results</article-title>. <source>JAMA</source>. <year>1983</year>;<volume>250</volume>(<issue>20</issue>):<fpage>2814</fpage>–<lpage>2819</lpage>.</citation>
</ref>
<ref id="bibr45-1074248413491496">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vantrimpont</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rouleau</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Wun</surname>
<given-names>CC</given-names>
</name>
<etal/>
</person-group>. <article-title>Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the survival and ventricular enlargement (SAVE) study. SAVE investigators</article-title>. <source>J Am Coll Cardiol</source>. <year>1997</year>;<volume>29</volume>(<issue>2</issue>):<fpage>229</fpage>–<lpage>236</lpage>.</citation>
</ref>
<ref id="bibr46-1074248413491496">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spargias</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Greenwood</surname>
<given-names>DC</given-names>
</name>
<etal/>
</person-group>. <article-title>Beta blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study</article-title>. <source>Heart</source>. <year>1999</year>;<volume>81</volume>(<issue>1</issue>):<fpage>25</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr47-1074248413491496">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freemantle</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Cleland</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mason</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>J.</given-names>
</name>
</person-group> <article-title>Beta blockade after myocardial infarction: Systematic review and meta regression analysis</article-title>. <source>BMJ</source>. <year>1999</year>;<volume>318</volume>(<issue>7200</issue>):<fpage>1730</fpage>–<lpage>1737</lpage>.</citation>
</ref>
<ref id="bibr48-1074248413491496">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gottlieb</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>McCarter</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>RA</given-names>
</name>
</person-group>. <article-title>Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction</article-title>. <source>N Engl J Med</source>. <year>1998</year>;<volume>339</volume>(<issue>8</issue>):<fpage>489</fpage>–<lpage>497</lpage>.</citation>
</ref>
<ref id="bibr49-1074248413491496">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chadda</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Byington</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Curb</surname>
<given-names>JD</given-names>
</name>
</person-group>. <article-title>Effect of propranolol after acute myocardial infarction in patients with congestive heart failure</article-title>. <source>Circulation</source>. <year>1986</year>;<volume>73</volume>(<issue>3</issue>):<fpage>503</fpage>–<lpage>510</lpage>.</citation>
</ref>
<ref id="bibr50-1074248413491496">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dargie</surname>
<given-names>HJ</given-names>
</name>
</person-group>. <article-title>Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial</article-title>. <source>Lancet</source>. <year>2001</year>;<volume>357</volume>(<issue>9266</issue>):<fpage>1385</fpage>–<lpage>1390</lpage>.</citation>
</ref>
<ref id="bibr51-1074248413491496">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McMurray</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kober</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the carvedilol post-infarct survival control in left ventricular dysfunction (CAPRICORN) trial</article-title>. <source>J Am Coll Cardiol</source>. <year>2005</year>;<volume>45</volume>(<issue>4</issue>):<fpage>525</fpage>–<lpage>530</lpage>.</citation>
</ref>
<ref id="bibr52-1074248413491496">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Packer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bristow</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Cohn</surname>
<given-names>JN</given-names>
</name>
<etal/>
</person-group>. <article-title>The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol heart failure study group</article-title>. <source>N Engl J Med</source>. <year>1996</year>;<volume>334</volume>(<issue>21</issue>):<fpage>1349</fpage>–<lpage>1355</lpage>.</citation>
</ref>
<ref id="bibr53-1074248413491496">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Packer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Coats</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Fowler</surname>
<given-names>MB</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of carvedilol on survival in severe chronic heart failure</article-title>. <source>N Engl J Med</source>. <year>2001</year>;<volume>344</volume>(<issue>22</issue>):<fpage>1651</fpage>–<lpage>1658</lpage>.</citation>
</ref>
<ref id="bibr54-1074248413491496">
<label>54</label>
<citation citation-type="journal">. <article-title>The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial</article-title>. <source>Lancet</source>. <year>1999</year>;<volume>353</volume>(<issue>9146</issue>):<fpage>9</fpage>–<lpage>13</lpage>
</citation>
</ref>
<ref id="bibr55-1074248413491496">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hjalmarson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fagerberg</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). MERIT-HF study group</article-title>. <source>JAMA</source>. <year>2000</year>;<volume>283</volume>(<issue>10</issue>):<fpage>1295</fpage>–<lpage>1302</lpage>.</citation>
</ref>
<ref id="bibr56-1074248413491496">
<label>56</label>
<citation citation-type="journal">
<collab collab-type="author">Beta-Blocker Evaluation of Survival Trial I</collab>. <article-title>A trial of the beta-blocker Bucindolol in patients with advanced chronic heart failure</article-title>. <source>N Engl J Med</source>. <year>2001</year>;<volume>344</volume>(<issue>22</issue>):<fpage>1659</fpage>–<lpage>1667</lpage>.</citation>
</ref>
<ref id="bibr57-1074248413491496">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Domanski</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Krause-Steinrauf</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Massie</surname>
<given-names>BM</given-names>
</name>
<etal/>
</person-group>. <article-title>A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS</article-title>. <source>J Card Fail</source>. <year>2003</year>;<volume>9</volume>(<issue>5</issue>):<fpage>354</fpage>–<lpage>363</lpage>.</citation>
</ref>
<ref id="bibr58-1074248413491496">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohlstein</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Douglas</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>CP</given-names>
</name>
<etal/>
</person-group>. <article-title>Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>1993</year>;<volume>90</volume>(<issue>13</issue>):<fpage>6189</fpage>–<lpage>6193</lpage>.</citation>
</ref>
<ref id="bibr59-1074248413491496">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neil-Dwyer</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bartlett</surname>
<given-names>J</given-names>
</name>
<name>
<surname>McAinsh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cruickshank</surname>
<given-names>JM</given-names>
</name>
</person-group>. <article-title>Beta-adrenoceptor blockers and the blood–brain barrier</article-title>. <source>Br J Clin Pharmacol</source>. <year>1981</year>;<volume>11</volume>(<issue>6</issue>):<fpage>549</fpage>–<lpage>553</lpage>.</citation>
</ref>
<ref id="bibr60-1074248413491496">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Metra</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Giubbini</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nodari</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Boldi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Modena</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Dei Cas</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol</article-title>. <source>Circulation</source>. <year>2000</year>;<volume>102</volume>(<issue>5</issue>):<fpage>546</fpage>–<lpage>551</lpage>.</citation>
</ref>
<ref id="bibr61-1074248413491496">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fonarow</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Albert</surname>
<given-names>NM</given-names>
</name>
<etal/>
</person-group>. <article-title>Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program</article-title>. <source>J Am Coll Cardiol</source>. <year>2008</year>;<volume>52</volume>(<issue>3</issue>):<fpage>190</fpage>–<lpage>199</lpage>.</citation>
</ref>
<ref id="bibr62-1074248413491496">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fiuzat</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wojdyla</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kitzman</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-action (heart failure: a controlled trial investigating outcomes of exercise training) trial</article-title>. <source>J Am Coll Cardiol</source>. <year>2012</year>;<volume>60</volume>(<issue>3</issue>):<fpage>208</fpage>–<lpage>215</lpage>.</citation>
</ref>
<ref id="bibr63-1074248413491496">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fonarow</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Albert</surname>
<given-names>NM</given-names>
</name>
<etal/>
</person-group>. <article-title>Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from organized program to initiate lifesaving treatment in hospitalized patients with heart failure)</article-title>. <source>Am J Cardiol</source>. <year>2008</year>;<volume>102</volume>(<issue>11</issue>):<fpage>1524</fpage>–<lpage>1529</lpage>.</citation>
</ref>
<ref id="bibr64-1074248413491496">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jessup</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>WT</given-names>
</name>
</person-group>, <article-title>Casey DE, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American college of cardiology foundation/American heart association task force on practice guidelines: developed in collaboration with the international society for heart and lung transplantation</article-title>. <source>Circulation</source>. <year>2009</year>;<volume>119</volume>(<issue>14</issue>):<fpage>1977</fpage>–<lpage>2016</lpage>.</citation>
</ref>
<ref id="bibr65-1074248413491496">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Hallstrom</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Epstein</surname>
<given-names>AE</given-names>
</name>
<etal/>
</person-group>. <article-title>Design and results of the antiarrhythmics vs implantable defibrillators (AVID) registry. The AVID investigators</article-title>. <source>Circulation</source>. <year>1999</year>;<volume>99</volume>(<issue>13</issue>):<fpage>1692</fpage>–<lpage>1699</lpage>.</citation>
</ref>
<ref id="bibr66-1074248413491496">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hreybe</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bedi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ezzeddine</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Indications for internal cardioverter defibrillator implantation predict time to first shock and the modulating effect of beta-blockers</article-title>. <source>Am Heart J</source>. <year>2005</year>;<volume>150</volume>(<issue>5</issue>):<fpage>1064</fpage>.</citation>
</ref>
<ref id="bibr67-1074248413491496">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Owan</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Hodge</surname>
<given-names>DO</given-names>
</name>
<name>
<surname>Herges</surname>
<given-names>RM</given-names>
</name>
<etal/>
</person-group>. <article-title>Trends in prevalence and outcome of heart failure with preserved ejection fraction</article-title>. <source>N Engl J Med</source>. <year>2006</year>;<volume>355</volume>(<issue>3</issue>):<fpage>251</fpage>–<lpage>259</lpage>.</citation>
</ref>
<ref id="bibr68-1074248413491496">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paulus</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Tschope</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sanderson</surname>
<given-names>JE</given-names>
</name>
<etal/>
</person-group>. <article-title>How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the heart failure and echocardiography associations of the European society of cardiology</article-title>. <source>Eur Heart J</source>. <year>2007</year>;<volume>28</volume>(<issue>20</issue>):<fpage>2539</fpage>–<lpage>2550</lpage>.</citation>
</ref>
<ref id="bibr69-1074248413491496">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Heerebeek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Borbely</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Niessen</surname>
<given-names>HW</given-names>
</name>
<etal/>
</person-group>. <article-title>Myocardial structure and function differ in systolic and diastolic heart failure</article-title>. <source>Circulation</source>. <year>2006</year>;<volume>113</volume>(<issue>16</issue>):<fpage>1966</fpage>–<lpage>1973</lpage>.</citation>
</ref>
<ref id="bibr70-1074248413491496">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cameron</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Kimura</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jackson-Burns</surname>
<given-names>DA</given-names>
</name>
<etal/>
</person-group>. <article-title>ATP-sensitive k+ channels are altered in hypertrophied ventricular myocytes</article-title>. <source>Am J Physiol</source>. <year>1988</year>;<volume>255</volume>(<issue>5 pt 2</issue>):<fpage>H1254</fpage>–<lpage>H1258</lpage>.</citation>
</ref>
<ref id="bibr71-1074248413491496">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rials</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Filart</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Marinchak</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Kowey</surname>
<given-names>PR</given-names>
</name>
</person-group>. <article-title>Regression of left ventricular hypertrophy with captopril restores normal ventricular action potential duration, dispersion of refractoriness, and vulnerability to inducible ventricular fibrillation</article-title>. <source>Circulation</source>. <year>1997</year>;<volume>96</volume>(<issue>4</issue>):<fpage>1330</fpage>–<lpage>1336</lpage>.</citation>
</ref>
<ref id="bibr72-1074248413491496">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koyanagi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Eastham</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Marcus</surname>
<given-names>ML</given-names>
</name>
</person-group>. <article-title>Effects of chronic hypertension and left ventricular hypertrophy on the incidence of sudden cardiac death after coronary artery occlusion in conscious dogs</article-title>. <source>Circulation</source>. <year>1982</year>;<volume>65</volume>(<issue>6</issue>):<fpage>1192</fpage>–<lpage>1197</lpage>.</citation>
</ref>
<ref id="bibr73-1074248413491496">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martins</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Marcus</surname>
<given-names>ML</given-names>
</name>
</person-group>. <article-title>Chronic hypertension and left ventricular hypertrophy facilitate induction of sustained ventricular tachycardia in dogs 3 hours after left circumflex coronary artery occlusion</article-title>. <source>J Am Coll Cardiol</source>. <year>1989</year>;<volume>14</volume>(<issue>5</issue>):<fpage>1365</fpage>–<lpage>1373</lpage>.</citation>
</ref>
<ref id="bibr74-1074248413491496">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kohya</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kimura</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Myerburg</surname>
<given-names>RJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Susceptibility of hypertrophied rat hearts to ventricular fibrillation during acute ischemia</article-title>. <source>J Mol Cell Cardiol</source>. <year>1988</year>;<volume>20</volume>(<issue>2</issue>):<fpage>159</fpage>–<lpage>168</lpage>.</citation>
</ref>
<ref id="bibr75-1074248413491496">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dobre</surname>
<given-names>D</given-names>
</name>
<name>
<surname>van Veldhuisen</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>DeJongste</surname>
<given-names>MJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival</article-title>. <source>Eur J Heart Fail</source>. <year>2007</year>;<volume>9</volume>(<issue>3</issue>):<fpage>280</fpage>–<lpage>286</lpage>.</citation>
</ref>
<ref id="bibr76-1074248413491496">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Massie</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Lukas</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>. <article-title>Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice</article-title>. <source>Am J Cardiol</source>. <year>2007</year>;<volume>99</volume>(<issue>9</issue>):<fpage>1263</fpage>–<lpage>1268</lpage>.</citation>
</ref>
<ref id="bibr77-1074248413491496">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flather</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Shibata</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Coats</surname>
<given-names>AJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Randomized trial to determine the effect of Nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (seniors)</article-title>. <source>Eur Heart J</source>. <year>2005</year>;<volume>26</volume>(<issue>3</issue>):<fpage>215</fpage>–<lpage>225</lpage>.</citation>
</ref>
<ref id="bibr78-1074248413491496">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schrier</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>WT</given-names>
</name>
</person-group>. <article-title>Hormones and hemodynamics in heart failure</article-title>. <source>N Engl J Med</source>. <year>1999</year>;<volume>341</volume>(<issue>8</issue>):<fpage>577</fpage>–<lpage>585</lpage>.</citation>
</ref>
<ref id="bibr79-1074248413491496">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sadoshima</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Izumo</surname>
<given-names>S.</given-names>
</name>
</person-group> <article-title>Molecular characterization of angiotensin II—induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the at1 receptor subtype</article-title>. <source>Circ Res</source>. <year>1993</year>;<volume>73</volume>(<issue>3</issue>):<fpage>413</fpage>–<lpage>423</lpage>.</citation>
</ref>
<ref id="bibr80-1074248413491496">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Urata</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Healy</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>RW</given-names>
</name>
<etal/>
</person-group>. <article-title>Angiotensin II-forming pathways in normal and failing human hearts</article-title>. <source>Circ Res</source>. <year>1990</year>;<volume>66</volume>(<issue>4</issue>):<fpage>883</fpage>–<lpage>890</lpage>.</citation>
</ref>
<ref id="bibr81-1074248413491496">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fang</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Raymond</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Blount</surname>
<given-names>JL</given-names>
</name>
<etal/>
</person-group>. <article-title>Dog mast cell alpha-chymase activates progelatinase b by cleaving the phe88-gln89 and phe91-glu92 bonds of the catalytic domain</article-title>. <source>J Biol Chem</source>. <year>1997</year>;<volume>272</volume>(<issue>41</issue>):<fpage>25628</fpage>–<lpage>25635</lpage>.</citation>
</ref>
<ref id="bibr82-1074248413491496">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunyady</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Catt</surname>
<given-names>KJ</given-names>
</name>
</person-group>. <article-title>Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II</article-title>. <source>Mol Endocrinol</source>. <year>2006</year>;<volume>20</volume>(<issue>5</issue>):<fpage>953</fpage>–<lpage>970</lpage>.</citation>
</ref>
<ref id="bibr83-1074248413491496">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Kats</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Duncker</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Haitsma</surname>
<given-names>DB</given-names>
</name>
<etal/>
</person-group>. <article-title>Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II</article-title>. <source>Circulation</source>. <year>2000</year>;<volume>102</volume>(<issue>13</issue>):<fpage>1556</fpage>–<lpage>1563</lpage>.</citation>
</ref>
<ref id="bibr84-1074248413491496">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>TT</given-names>
</name>
<name>
<surname>Takimoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>AF</given-names>
</name>
<etal/>
</person-group>. <article-title>Independent regulation of cardiac Kv4.3 potassium channel expression by angiotensin II and phenylephrine</article-title>. <source>Circ Res</source>. <year>2001</year>;<volume>88</volume>(<issue>5</issue>):<fpage>476</fpage>–<lpage>482</lpage>.</citation>
</ref>
<ref id="bibr85-1074248413491496">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McIntosh</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Cobbe</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Kane</surname>
<given-names>KA</given-names>
</name>
<etal/>
</person-group>. <article-title>Action potential prolongation and potassium currents in left-ventricular myocytes isolated from hypertrophied rabbit hearts</article-title>. <source>J Mol Cell Cardiol</source>. <year>1998</year>;<volume>30</volume>(<issue>1</issue>):<fpage>43</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr86-1074248413491496">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomita</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bassett</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Myerburg</surname>
<given-names>RJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Diminished transient outward currents in rat hypertrophied ventricular myocytes</article-title>. <source>Circ Res</source>. <year>1994</year>;<volume>75</volume>(<issue>2</issue>):<fpage>296</fpage>–<lpage>303</lpage>.</citation>
</ref>
<ref id="bibr87-1074248413491496">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nabauer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kaab</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Potassium channel down-regulation in heart failure</article-title>. <source>Cardiovasc Res</source>. <year>1998</year>;<volume>37</volume>(<issue>2</issue>):<fpage>324</fpage>–<lpage>334</lpage>.</citation>
</ref>
<ref id="bibr88-1074248413491496">
<label>88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>WP</given-names>
</name>
<etal/>
</person-group>. <article-title>Angiotensin II increases expression of alpha1C subunit of L-type calcium channel through a reactive oxygen species and cAMP response element-binding protein-dependent pathway in HL-1 myocytes</article-title>. <source>Circ Res</source>. <year>2007</year>;<volume>100</volume>(<issue>10</issue>):<fpage>1476</fpage>–<lpage>1485</lpage>.</citation>
</ref>
<ref id="bibr89-1074248413491496">
<label>89</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname>
<given-names>HD</given-names>
</name>
<name>
<surname>Fuchs</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>DJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death</article-title>. <source>Am J Pathol</source>. <year>2004</year>;<volume>165</volume>(<issue>3</issue>):<fpage>1019</fpage>–<lpage>1032</lpage>.</citation>
</ref>
<ref id="bibr90-1074248413491496">
<label>90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vermes</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tardif</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Bourassa</surname>
<given-names>MG</given-names>
</name>
<etal/>
</person-group>. <article-title>Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the studies of left ventricular dysfunction (SOLVD) trials</article-title>. <source>Circulation</source>. <year>2003</year>;<volume>107</volume>(<issue>23</issue>):<fpage>2926</fpage>–<lpage>2931</lpage>.</citation>
</ref>
<ref id="bibr91-1074248413491496">
<label>91</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pedersen</surname>
<given-names>OD</given-names>
</name>
<name>
<surname>Bagger</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kober</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction</article-title>. <source>Circulation</source>. <year>1999</year>;<volume>100</volume>(<issue>4</issue>):<fpage>376</fpage>–<lpage>380</lpage>.</citation>
</ref>
<ref id="bibr92-1074248413491496">
<label>92</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madrid</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Bueno</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Rebollo</surname>
<given-names>JM</given-names>
</name>
<etal/>
</person-group>. <article-title>Use of Irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study</article-title>. <source>Circulation</source>. <year>2002</year>;<volume>106</volume>(<issue>3</issue>):<fpage>331</fpage>–<lpage>336</lpage>.</citation>
</ref>
<ref id="bibr93-1074248413491496">
<label> 93</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Minisi</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Thames</surname>
<given-names>MD</given-names>
</name>
</person-group>. <article-title>Distribution of left ventricular sympathetic afferents demonstrated by reflex responses to transmural myocardial ischemia and to intracoronary and epicardial bradykinin</article-title>. <source>Circulation</source>. <year>1993</year>;<volume>87</volume>(<issue>1</issue>):<fpage>240</fpage>–<lpage>246</lpage>.</citation>
</ref>
<ref id="bibr94-1074248413491496">
<label> 94</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Castellano</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Juneman</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Pretreatment with angiotensin receptor blockade prevents left ventricular dysfunction and blunts left ventricular remodeling associated with acute myocardial infarction</article-title>. <source>Circulation</source>. <year>2006</year>;<volume>114</volume>(<issue>18</issue>):<fpage>1933</fpage>–<lpage>1939</lpage>.</citation>
</ref>
<ref id="bibr95-1074248413491496">
<label> 95</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zannad</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dousset</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Alla</surname>
<given-names>F.</given-names>
</name>
</person-group> <article-title>Treatment of congestive heart failure: Interfering the aldosterone-cardiac extracellular matrix relationship</article-title>. <source>Hypertension</source>. <year>2001</year>;<volume>38</volume>(<issue>5</issue>):<fpage>1227</fpage>–<lpage>1232</lpage>.</citation>
</ref>
<ref id="bibr96-1074248413491496">
<label> 96</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zannad</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Alla</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dousset</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). RALES investigators</article-title>. <source>Circulation</source>. <year>2000</year>;<volume>102</volume>(<issue>22</issue>):<fpage>2700</fpage>–<lpage>2706</lpage>.</citation>
</ref>
<ref id="bibr97-1074248413491496">
<label> 97</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rutherford</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Pfeffer</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Moye</surname>
<given-names>LA</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of captopril on ischemic events after myocardial infarction. Results of the survival and ventricular enlargement trial. SAVE investigators</article-title>. <source>Circulation</source>. <year>1994</year>;<volume>90</volume>(<issue>4</issue>):<fpage>1731</fpage>–<lpage>1738</lpage>.</citation>
</ref>
<ref id="bibr98-1074248413491496">
<label> 98</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kober</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Torp-Pedersen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Carlsen</surname>
<given-names>JE</given-names>
</name>
<etal/>
</person-group>. <article-title>A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. trandolapril cardiac evaluation (TRACE) study group</article-title>. <source>N Engl J Med</source>. <year>1995</year>;<volume>333</volume>(<issue>25</issue>):<fpage>1670</fpage>–<lpage>1676</lpage>.</citation>
</ref>
<ref id="bibr99-1074248413491496">
<label> 99</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cleland</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Erhardt</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE study investigators</article-title>. <source>Eur Heart J</source>. <year>1997</year>;<volume>18</volume>(<issue>1</issue>):<fpage>41</fpage>–<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr100-1074248413491496">
<label>100</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Domanski</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Exner</surname>
<given-names>DV</given-names>
</name>
<name>
<surname>Borkowf</surname>
<given-names>CB</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials</article-title>. <source>J Am Coll Cardiol</source>. <year>1999</year>;<volume>33</volume>(<issue>3</issue>):<fpage>598</fpage>–<lpage>604</lpage>.</citation>
</ref>
<ref id="bibr101-1074248413491496">
<label>101</label>
<citation citation-type="journal">
<collab collab-type="author">Effects of Enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)</collab>. <article-title>The consensus trial study group</article-title>. <source>N Engl J Med</source>. <year>1987</year>;<volume>316</volume>(<issue>23</issue>):<fpage>1429</fpage>–<lpage>1435</lpage>.</citation>
</ref>
<ref id="bibr102-1074248413491496">
<label>102</label>
<citation citation-type="journal">
<collab collab-type="author">Effect of Enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions</collab>. <article-title>The SOLVD investigators</article-title>. <source>N Engl J Med</source>. <year>1992</year>;<volume>327</volume>(<issue>10</issue>):<fpage>685</fpage>–<lpage>691</lpage>.</citation>
</ref>
<ref id="bibr103-1074248413491496">
<label>103</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohn</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ziesche</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>A comparison of Enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure</article-title>. <source>N Engl J Med</source>. <year>1991</year>;<volume>325</volume>(<issue>5</issue>):<fpage>303</fpage>–<lpage>310</lpage>.</citation>
</ref>
<ref id="bibr104-1074248413491496">
<label>104</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pitt</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Segal</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>FA</given-names>
</name>
<etal/>
</person-group>. <article-title>Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE)</article-title>. <source>Lancet</source>. <year>1997</year>;<volume>349</volume>(<issue>9054</issue>):<fpage>747</fpage>–<lpage>752</lpage>.</citation>
</ref>
<ref id="bibr105-1074248413491496">
<label>105</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McMurray</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Ostergren</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Swedberg</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of Candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-ADDED trial</article-title>. <source>Lancet</source>. <year>2003</year>;<volume>362</volume>(<issue>9386</issue>):<fpage>767</fpage>–<lpage>771</lpage>.</citation>
</ref>
<ref id="bibr106-1074248413491496">
<label>106</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohn</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Tognoni</surname>
<given-names>G</given-names>
</name>
</person-group>; <collab collab-type="author">valsartan Heart Failure Trial Investigators</collab>. <article-title>A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure</article-title>. <source>N Engl J Med</source>. <year>2001</year>;<volume>345</volume>(<issue>23</issue>):<fpage>1667</fpage>–<lpage>1675</lpage>.</citation>
</ref>
<ref id="bibr107-1074248413491496">
<label>107</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pfeffer</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>McMurray</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Velazquez</surname>
<given-names>EJ</given-names>
</name>
<etal/>
</person-group>. <article-title>valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both</article-title>. <source>N Engl J Med</source>. <year>2003</year>;<volume>349</volume>(<issue>20</issue>):<fpage>1893</fpage>–<lpage>1906</lpage>.</citation>
</ref>
<ref id="bibr108-1074248413491496">
<label>108</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pitt</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Poole-Wilson</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Segal</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the losartan heart failure survival study ELITE II</article-title>. <source>Lancet</source>. <year>2000</year>;<volume>355</volume>(<issue>9215</issue>):<fpage>1582</fpage>–<lpage>1587</lpage>.</citation>
</ref>
<ref id="bibr109-1074248413491496">
<label>109</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Konstam</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Neaton</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Dickstein</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial</article-title>. <source>Lancet</source>. <year>2009</year>;<volume>374</volume>(<issue>9704</issue>):<fpage>1840</fpage>–<lpage>1848</lpage>.</citation>
</ref>
<ref id="bibr110-1074248413491496">
<label>110</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Granger</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>McMurray</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Yusuf</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of Candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial</article-title>. <source>Lancet</source>. <year>2003</year>;<volume>362</volume>(<issue>9386</issue>):<fpage>772</fpage>–<lpage>776</lpage>.</citation>
</ref>
<ref id="bibr111-1074248413491496">
<label>111</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gring</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>GS</given-names>
</name>
</person-group>. <article-title>A hard look at angiotensin receptor blockers in heart failure</article-title>. <source>J Am Coll Cardiol</source>. <year>2004</year>;<volume>44</volume>(<issue>9</issue>):<fpage>1841</fpage>–<lpage>1846</lpage>.</citation>
</ref>
<ref id="bibr112-1074248413491496">
<label>112</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pitt</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zannad</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Remme</surname>
<given-names>WJ</given-names>
</name>
<etal/>
</person-group>. <article-title>The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study investigators</article-title>. <source>N Engl J Med</source>. <year>1999</year>;<volume>341</volume>(<issue>10</issue>):<fpage>709</fpage>–<lpage>717</lpage>.</citation>
</ref>
<ref id="bibr113-1074248413491496">
<label>113</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pitt</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Remme</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zannad</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction</article-title>. <source>N Engl J Med</source>. <year>2003</year>;<volume>348</volume>(<issue>14</issue>):<fpage>1309</fpage>–<lpage>1321</lpage>.</citation>
</ref>
<ref id="bibr114-1074248413491496">
<label>114</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Meara</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Khairy</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Blanchet</surname>
<given-names>MC</given-names>
</name>
<etal/>
</person-group>. <article-title>Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the atrial fibrillation and congestive heart failure trial</article-title>. <source>Circ Heart Fail</source>. <year>2012</year>;<volume>5</volume>(<issue>5</issue>):<fpage>586</fpage>–<lpage>593</lpage>.</citation>
</ref>
<ref id="bibr115-1074248413491496">
<label>115</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wachtell</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Okin</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Olsen</surname>
<given-names>MH</given-names>
</name>
<etal/>
</person-group>. <article-title>Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE study</article-title>. <source>Circulation</source>. <year>2007</year>;<volume>116</volume>(<issue>7</issue>):<fpage>700</fpage>–<lpage>705</lpage>.</citation>
</ref>
<ref id="bibr116-1074248413491496">
<label>116</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cleland</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Tendera</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Adamus</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Freemantle</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Polonski</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>The Perindopril in elderly people with chronic heart failure (PEP-CHF) study</article-title>. <source>Eur Heart J</source>. <year>2006</year>;<volume>27</volume>(<issue>19</issue>):<fpage>2338</fpage>–<lpage>2345</lpage>.</citation>
</ref>
<ref id="bibr117-1074248413491496">
<label>117</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yusuf</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pfeffer</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Swedberg</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of Candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial</article-title>. <source>Lancet</source>. <year>2003</year>;<volume>362</volume>(<issue>9386</issue>):<fpage>777</fpage>–<lpage>781</lpage>.</citation>
</ref>
<ref id="bibr118-1074248413491496">
<label>118</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Persson</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lonn</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Edner</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence: results from the CHARM Echocardiographic Substudy-CHARMES</article-title>. <source>J Am Coll Cardiol</source>. <year>2007</year>;<volume>49</volume>(<issue>6</issue>):<fpage>687</fpage>–<lpage>694</lpage>.</citation>
</ref>
<ref id="bibr119-1074248413491496">
<label>119</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lang</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Bierig</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Devereux</surname>
<given-names>RB</given-names>
</name>
<etal/>
</person-group>. <article-title>Recommendations for chamber quantification</article-title>. <source>Eur J Echocardiogr</source>. <year>2006</year>;<volume>7</volume>(<issue>2</issue>):<fpage>79</fpage>–<lpage>108</lpage>.</citation>
</ref>
<ref id="bibr120-1074248413491496">
<label>120</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Massie</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Carson</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>McMurray</surname>
<given-names>JJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Irbesartan in patients with heart failure and preserved ejection fraction</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>359</volume>(<issue>23</issue>):<fpage>2456</fpage>–<lpage>2467</lpage>.</citation>
</ref>
<ref id="bibr121-1074248413491496">
<label>121</label>
<citation citation-type="journal"> <article-title>Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4s)</article-title>. <source>Lancet</source>. <year>1994</year>;<volume>344</volume>(<issue>8934</issue>):<fpage>1383</fpage>–<lpage>1389</lpage>.</citation>
</ref>
<ref id="bibr122-1074248413491496">
<label>122</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sacks</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Pfeffer</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Moye</surname>
<given-names>LA</given-names>
</name>
<etal/>
</person-group>. <article-title>The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators</article-title>. <source>N Engl J Med</source>. <year>1996</year>;<volume>335</volume>(<issue>14</issue>):<fpage>1001</fpage>–<lpage>1009</lpage>.</citation>
</ref>
<ref id="bibr123-1074248413491496">
<label>123</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>LaRosa</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Grundy</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Waters</surname>
<given-names>DD</given-names>
</name>
<etal/>
</person-group>. <article-title>Intensive lipid lowering with Atorvastatin in patients with stable coronary disease</article-title>. <source>N Engl J Med</source>. <year>2005</year>;<volume>352</volume>(<issue>14</issue>):<fpage>1425</fpage>–<lpage>1435</lpage>.</citation>
</ref>
<ref id="bibr124-1074248413491496">
<label>124</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nissen</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Nicholls</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Sipahi</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the asteroid trial</article-title>. <source>JAMA</source>. <year>2006</year>;<volume>295</volume>(<issue>13</issue>):<fpage>1556</fpage>–<lpage>1565</lpage>.</citation>
</ref>
<ref id="bibr125-1074248413491496">
<label>125</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cascio</surname>
<given-names>WE</given-names>
</name>
</person-group>. <article-title>Myocardial ischemia: what factors determine arrhythmogenesis?</article-title> <source>J Cardiovasc Electrophysiol</source>. <year>2001</year>;<volume>12</volume>(<issue>6</issue>):<fpage>726</fpage>–<lpage>729</lpage>.</citation>
</ref>
<ref id="bibr126-1074248413491496">
<label>126</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laufs</surname>
<given-names>U</given-names>
</name>
<name>
<surname>La Fata</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Plutzky</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Upregulation of endothelial nitric oxide synthase by hmg coa reductase inhibitors</article-title>. <source>Circulation</source>. <year>1998</year>;<volume>97</volume>(<issue>12</issue>):<fpage>1129</fpage>–<lpage>1135</lpage>.</citation>
</ref>
<ref id="bibr127-1074248413491496">
<label>127</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rikitake</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kawashima</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Takeshita</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits</article-title>. <source>Atherosclerosis</source>. <year>2001</year>;<volume>154</volume>(<issue>1</issue>):<fpage>87</fpage>–<lpage>96</lpage>.</citation>
</ref>
<ref id="bibr128-1074248413491496">
<label>128</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ridker</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Rifai</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Pfeffer</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>. <article-title>Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events (CARE) investigators</article-title>. <source>Circulation</source>. <year>1998</year>;<volume>98</volume>(<issue>9</issue>):<fpage>839</fpage>–<lpage>844</lpage>.</citation>
</ref>
<ref id="bibr129-1074248413491496">
<label>129</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weber</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Anversa</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Armstrong</surname>
<given-names>PW</given-names>
</name>
<etal/>
</person-group>. <article-title>Remodeling and reparation of the cardiovascular system</article-title>. <source>J Am Coll Cardiol</source>. <year>1992</year>;<volume>20</volume>(<issue>1</issue>):<fpage>3</fpage>–<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr130-1074248413491496">
<label>130</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Chou</surname>
<given-names>TF</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>CH</given-names>
</name>
</person-group>. <article-title>Effects of pravastatin on cardiomyocyte hypertrophy and ventricular vulnerability in normolipidemic rats after myocardial infarction</article-title>. <source>J Mol Cell Cardiol</source>. <year>2003</year>;<volume>35</volume>(<issue>12</issue>):<fpage>1449</fpage>–<lpage>1459</lpage>.</citation>
</ref>
<ref id="bibr131-1074248413491496">
<label>131</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sola</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mir</surname>
<given-names>MQ</given-names>
</name>
<name>
<surname>Lerakis</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure</article-title>. <source>J Am Coll Cardiol</source>. <year>2006</year>;<volume>47</volume>(<issue>2</issue>):<fpage>332</fpage>–<lpage>337</lpage>.</citation>
</ref>
<ref id="bibr132-1074248413491496">
<label>132</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Node</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kitakaze</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hori</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>JK</given-names>
</name>
</person-group>. <article-title>Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy</article-title>. <source>Circulation</source>. <year>2003</year>;<volume>108</volume>(<issue>7</issue>):<fpage>839</fpage>–<lpage>843</lpage>.</citation>
</ref>
<ref id="bibr133-1074248413491496">
<label>133</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Iyer</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Cimato</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Canty</surname>
<given-names>JM</given-names>
<suffix>Jr</suffix>
</name>
</person-group>. <article-title>Pravastatin improves function in hibernating myocardium by mobilizing CD133+ and cKit+ bone marrow progenitor cells and promoting myocytes to reenter the growth phase of the cardiac cell cycle</article-title>. <source>Circ Res</source>. <year>2009</year>;<volume>104</volume>(<issue>2</issue>):<fpage>255</fpage>–<lpage>264</lpage>.</citation>
</ref>
<ref id="bibr134-1074248413491496">
<label>134</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vrtovec</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Okrajsek</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Golicnik</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTC interval duration in patients with advanced chronic heart failure</article-title>. <source>J Card Fail</source>. <year>2005</year>;<volume>11</volume>(<issue>9</issue>):<fpage>684</fpage>–<lpage>690</lpage>.</citation>
</ref>
<ref id="bibr135-1074248413491496">
<label>135</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pehlivanidis</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Athyros</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Demitriadis</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Papageorgiou</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Bouloukos</surname>
<given-names>VJ</given-names>
</name>
<name>
<surname>Kontopoulos</surname>
<given-names>AG</given-names>
</name>
</person-group>. <article-title>Heart rate variability after long-term treatment with Atorvastatin in hypercholesterolaemic patients with or without coronary artery disease</article-title>. <source>Atherosclerosis</source>. <year>2001</year>;<volume>157</volume>(<issue>2</issue>):<fpage>463</fpage>–<lpage>469</lpage>.</citation>
</ref>
<ref id="bibr136-1074248413491496">
<label>136</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pedersen</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Faergeman</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Kastelein</surname>
<given-names>JJ</given-names>
</name>
<etal/>
</person-group>. <article-title>High-dose Atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the ideal study: a randomized controlled trial</article-title>. <source>JAMA</source>. <year>2005</year>;<volume>294</volume>(<issue>19</issue>):<fpage>2437</fpage>–<lpage>2445</lpage>.</citation>
</ref>
<ref id="bibr137-1074248413491496">
<label>137</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>LaRosa</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Grundy</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Waters</surname>
<given-names>DD</given-names>
</name>
<etal/>
</person-group>. <article-title>Intensive lipid lowering with Atorvastatin in patients with stable coronary disease</article-title>. <source>N Engl J Med</source>. <year>2005</year>;<volume>352</volume>(<issue>14</issue>):<fpage>1425</fpage>–<lpage>1435</lpage>.</citation>
</ref>
<ref id="bibr138-1074248413491496">
<label>138</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fonarow</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Spencer</surname>
<given-names>FA</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality</article-title>. <source>Am J Cardiol</source>. <year>2005</year>;<volume>96</volume>(<issue>5</issue>):<fpage>611</fpage>–<lpage>616</lpage>.</citation>
</ref>
<ref id="bibr139-1074248413491496">
<label>139</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitchell</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Powell</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Gillis</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Kehl</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Hallstrom</surname>
<given-names>AP</given-names>
</name>
</person-group>. <article-title>Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the antiarrhythmics versus implantable defibrillators (AVID) trial</article-title>. <source>J Am Coll Cardiol</source>. <year>2003</year>;<volume>42</volume>(<issue>1</issue>):<fpage>81</fpage>–<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr140-1074248413491496">
<label>140</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vyas</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Moss</surname>
<given-names>AJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Reduction in ventricular tachyarrhythmias with statins in the multicenter automatic defibrillator implantation trial (MADIT)-II</article-title>. <source>J Am Coll Cardiol</source>. <year>2006</year>;<volume>47</volume>(<issue>4</issue>):<fpage>769</fpage>–<lpage>773</lpage>.</citation>
</ref>
<ref id="bibr141-1074248413491496">
<label>141</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dickinson</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Ip</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Olshansky</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the sudden cardiac death in heart failure trial (SCD-HEFT)</article-title>. <source>Am Heart J</source>. <year>2007</year>;<volume>153</volume>(<issue>4</issue>):<fpage>573</fpage>–<lpage>578</lpage>.</citation>
</ref>
<ref id="bibr142-1074248413491496">
<label>142</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldberger</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Subacius</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schaechter</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy</article-title>. <source>J Am Coll Cardiol</source>. <year>2006</year>;<volume>48</volume>(<issue>6</issue>):<fpage>1228</fpage>–<lpage>1233</lpage>.</citation>
</ref>
<ref id="bibr143-1074248413491496">
<label>143</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buber</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Goldenberg</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Moss</surname>
<given-names>AJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Reduction in life-threatening ventricular tachyarrhythmias in statin-treated patients with nonischemic cardiomyopathy enrolled in the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy)</article-title>. <source>J Am Coll Cardiol</source>. <year>2012</year>;<volume>60</volume>(<issue>8</issue>):<fpage>749</fpage>–<lpage>755</lpage>.</citation>
</ref>
<ref id="bibr144-1074248413491496">
<label>144</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kjekshus</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Apetrei</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Barrios</surname>
<given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>Rosuvastatin in older patients with systolic heart failure</article-title>. <source>N Engl J Med</source>. <year>2007</year>;<volume>357</volume>(<issue>22</issue>):<fpage>2248</fpage>–<lpage>2261</lpage>.</citation>
</ref>
<ref id="bibr145-1074248413491496">
<label>145</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gissi</surname>
<given-names>HFI</given-names>
</name>
<name>
<surname>Tavazzi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Maggioni</surname>
<given-names>AP</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of Rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet</source>. <year>2008</year>;<volume>372</volume>(<issue>9645</issue>):<fpage>1231</fpage>–<lpage>1239</lpage>.</citation>
</ref>
<ref id="bibr146-1074248413491496">
<label>146</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tuzcu</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Kapadia</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Tutar</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound</article-title>. <source>Circulation</source>. <year>2001</year>;<volume>103</volume>(<issue>22</issue>):<fpage>2705</fpage>–<lpage>2710</lpage>.</citation>
</ref>
<ref id="bibr147-1074248413491496">
<label>147</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>D'Agostino</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Prediction of coronary heart disease using risk factor categories</article-title>. <source>Circulation</source>. <year>1998</year>;<volume>97</volume>(<issue>18</issue>):<fpage>1837</fpage>–<lpage>1847</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>